BRPI0707338A2 - derivados de imidazol, composições, e métodos substituìdos de uso como inibidores de ptpase - Google Patents
derivados de imidazol, composições, e métodos substituìdos de uso como inibidores de ptpase Download PDFInfo
- Publication number
- BRPI0707338A2 BRPI0707338A2 BRPI0707338-0A BRPI0707338A BRPI0707338A2 BR PI0707338 A2 BRPI0707338 A2 BR PI0707338A2 BR PI0707338 A BRPI0707338 A BR PI0707338A BR PI0707338 A2 BRPI0707338 A2 BR PI0707338A2
- Authority
- BR
- Brazil
- Prior art keywords
- phenyl
- alkyl
- dichloro
- imidazol
- formula
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract description 21
- 238000000034 method Methods 0.000 title abstract description 387
- 239000000203 mixture Substances 0.000 title abstract description 102
- 150000002460 imidazoles Chemical class 0.000 title abstract description 8
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 title abstract description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 220
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 31
- 201000010099 disease Diseases 0.000 claims abstract description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 23
- 238000002360 preparation method Methods 0.000 claims abstract description 18
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims abstract description 10
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims abstract description 10
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 9
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims abstract description 8
- 230000001404 mediated effect Effects 0.000 claims abstract description 8
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 7
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 7
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 claims abstract description 4
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 claims abstract description 4
- -1 4,5-diazaindanyl Chemical group 0.000 claims description 411
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims description 177
- 125000000217 alkyl group Chemical group 0.000 claims description 123
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 90
- 229910052739 hydrogen Inorganic materials 0.000 claims description 84
- 239000001257 hydrogen Substances 0.000 claims description 79
- 229910052799 carbon Inorganic materials 0.000 claims description 60
- 239000002253 acid Substances 0.000 claims description 57
- 150000003839 salts Chemical class 0.000 claims description 56
- 125000003118 aryl group Chemical group 0.000 claims description 54
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 50
- 229910052757 nitrogen Chemical group 0.000 claims description 46
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 42
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 37
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 29
- 125000002947 alkylene group Chemical group 0.000 claims description 28
- 125000000623 heterocyclic group Chemical group 0.000 claims description 28
- 125000000304 alkynyl group Chemical group 0.000 claims description 27
- 229910052721 tungsten Inorganic materials 0.000 claims description 27
- 125000001072 heteroaryl group Chemical group 0.000 claims description 25
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 24
- 125000003342 alkenyl group Chemical group 0.000 claims description 23
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 23
- 229910052727 yttrium Inorganic materials 0.000 claims description 22
- 229910052736 halogen Inorganic materials 0.000 claims description 21
- 125000001424 substituent group Chemical group 0.000 claims description 21
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 20
- 125000001188 haloalkyl group Chemical group 0.000 claims description 19
- 238000004519 manufacturing process Methods 0.000 claims description 18
- 125000004432 carbon atom Chemical group C* 0.000 claims description 17
- 239000000460 chlorine Substances 0.000 claims description 15
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 15
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 15
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 14
- 125000005843 halogen group Chemical group 0.000 claims description 14
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 14
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 13
- 230000015572 biosynthetic process Effects 0.000 claims description 13
- 125000005842 heteroatom Chemical group 0.000 claims description 13
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims description 13
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 12
- 230000002401 inhibitory effect Effects 0.000 claims description 12
- 229910052760 oxygen Inorganic materials 0.000 claims description 12
- 125000005275 alkylenearyl group Chemical group 0.000 claims description 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 11
- 239000001301 oxygen Substances 0.000 claims description 11
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 11
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 10
- 229910052801 chlorine Inorganic materials 0.000 claims description 10
- 208000026278 immune system disease Diseases 0.000 claims description 10
- 239000012453 solvate Substances 0.000 claims description 10
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- 238000003786 synthesis reaction Methods 0.000 claims description 10
- 229940124597 therapeutic agent Drugs 0.000 claims description 10
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 9
- 239000011593 sulfur Chemical group 0.000 claims description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 8
- 102000018997 Growth Hormone Human genes 0.000 claims description 8
- 108010051696 Growth Hormone Proteins 0.000 claims description 8
- 125000004450 alkenylene group Chemical group 0.000 claims description 8
- 125000004429 atom Chemical group 0.000 claims description 8
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 8
- 239000000122 growth hormone Substances 0.000 claims description 8
- 229940002612 prodrug Drugs 0.000 claims description 8
- 239000000651 prodrug Substances 0.000 claims description 8
- 229910052702 rhenium Inorganic materials 0.000 claims description 8
- 102000004877 Insulin Human genes 0.000 claims description 7
- 108090001061 Insulin Proteins 0.000 claims description 7
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims description 7
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- 229940088597 hormone Drugs 0.000 claims description 7
- 239000005556 hormone Substances 0.000 claims description 7
- 229940125396 insulin Drugs 0.000 claims description 7
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 6
- 150000002500 ions Chemical class 0.000 claims description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 6
- YQDGQEKUTLYWJU-UHFFFAOYSA-N 5,6,7,8-tetrahydroquinoline Chemical compound C1=CC=C2CCCCC2=N1 YQDGQEKUTLYWJU-UHFFFAOYSA-N 0.000 claims description 5
- 208000030507 AIDS Diseases 0.000 claims description 5
- 208000035473 Communicable disease Diseases 0.000 claims description 5
- 102000004127 Cytokines Human genes 0.000 claims description 5
- 108090000695 Cytokines Proteins 0.000 claims description 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 5
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 5
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims description 5
- 125000005218 alkyleneheteroaryl group Chemical group 0.000 claims description 5
- 208000026935 allergic disease Diseases 0.000 claims description 5
- XTKDAFGWCDAMPY-UHFFFAOYSA-N azaperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCN(C=2N=CC=CC=2)CC1 XTKDAFGWCDAMPY-UHFFFAOYSA-N 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 5
- 239000011737 fluorine Substances 0.000 claims description 5
- 229910052731 fluorine Inorganic materials 0.000 claims description 5
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 5
- 208000027866 inflammatory disease Diseases 0.000 claims description 5
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 5
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims description 5
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims description 4
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims description 4
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims description 4
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims description 4
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 4
- 239000012190 activator Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 229940125753 fibrate Drugs 0.000 claims description 4
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 3
- 229940123208 Biguanide Drugs 0.000 claims description 3
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 claims description 3
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims description 3
- 229940122199 Insulin secretagogue Drugs 0.000 claims description 3
- 229940122355 Insulin sensitizer Drugs 0.000 claims description 3
- 229960002632 acarbose Drugs 0.000 claims description 3
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 claims description 3
- 229930013930 alkaloid Natural products 0.000 claims description 3
- 239000002168 alkylating agent Substances 0.000 claims description 3
- 229940100198 alkylating agent Drugs 0.000 claims description 3
- 230000000340 anti-metabolite Effects 0.000 claims description 3
- 239000000935 antidepressant agent Substances 0.000 claims description 3
- 229940005513 antidepressants Drugs 0.000 claims description 3
- 229940100197 antimetabolite Drugs 0.000 claims description 3
- 239000002256 antimetabolite Substances 0.000 claims description 3
- 239000003862 glucocorticoid Substances 0.000 claims description 3
- 239000003102 growth factor Substances 0.000 claims description 3
- UCFFGYASXIPWPD-UHFFFAOYSA-N methyl hypochlorite Chemical compound COCl UCFFGYASXIPWPD-UHFFFAOYSA-N 0.000 claims description 3
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 claims description 3
- BILOVEKAXJZPHK-UHFFFAOYSA-N 5-[3-[2-[[4-[4-(2-cyclohexylethoxy)phenyl]phenyl]methyl]-4-(2,4-dichlorophenyl)imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound ClC1=CC(Cl)=CC=C1C1=CN(C=2C=C(C=CC=2)N2S(NC(=O)C2)(=O)=O)C(CC=2C=CC(=CC=2)C=2C=CC(OCCC3CCCCC3)=CC=2)=N1 BILOVEKAXJZPHK-UHFFFAOYSA-N 0.000 claims description 2
- 229920001268 Cholestyramine Polymers 0.000 claims description 2
- 229940122041 Cholinesterase inhibitor Drugs 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 101001032756 Rattus norvegicus Granzyme-like protein 1 Proteins 0.000 claims description 2
- 229940100389 Sulfonylurea Drugs 0.000 claims description 2
- 239000001961 anticonvulsive agent Substances 0.000 claims description 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 2
- 239000000544 cholinesterase inhibitor Substances 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 150000002431 hydrogen Chemical group 0.000 claims 8
- UUWKMTNJQZLBMA-UHFFFAOYSA-N 5-[3-[4-(2,4-dichlorophenyl)-2-[[4-[3-(2-phenylethoxy)phenyl]phenyl]methyl]imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound ClC1=CC(Cl)=CC=C1C1=CN(C=2C=C(C=CC=2)N2S(NC(=O)C2)(=O)=O)C(CC=2C=CC(=CC=2)C=2C=C(OCCC=3C=CC=CC=3)C=CC=2)=N1 UUWKMTNJQZLBMA-UHFFFAOYSA-N 0.000 claims 1
- CENWRJLRKOPSID-UHFFFAOYSA-N 5-[3-[4-(2,4-dichlorophenyl)-2-[[4-[3-(3,3-dimethylbutoxy)phenyl]phenyl]methyl]imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound CC(C)(C)CCOC1=CC=CC(C=2C=CC(CC=3N(C=C(N=3)C=3C(=CC(Cl)=CC=3)Cl)C=3C=C(C=CC=3)N3S(NC(=O)C3)(=O)=O)=CC=2)=C1 CENWRJLRKOPSID-UHFFFAOYSA-N 0.000 claims 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims 1
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 claims 1
- 101150100019 NRDC gene Proteins 0.000 claims 1
- 229940126033 PPAR agonist Drugs 0.000 claims 1
- 229910006069 SO3H Inorganic materials 0.000 claims 1
- 150000003797 alkaloid derivatives Chemical class 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 claims 1
- 230000001773 anti-convulsant effect Effects 0.000 claims 1
- 230000001430 anti-depressive effect Effects 0.000 claims 1
- 230000000561 anti-psychotic effect Effects 0.000 claims 1
- 229960003965 antiepileptics Drugs 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 230000008512 biological response Effects 0.000 claims 1
- 239000004305 biphenyl Substances 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 239000003607 modifier Substances 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 230000004768 organ dysfunction Effects 0.000 claims 1
- 239000002307 peroxisome proliferator activated receptor agonist Substances 0.000 claims 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical class C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 abstract description 65
- 230000000694 effects Effects 0.000 abstract description 12
- 208000035475 disorder Diseases 0.000 abstract description 8
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract description 3
- 241001465754 Metazoa Species 0.000 abstract description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract description 3
- 239000013589 supplement Substances 0.000 abstract 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 179
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 162
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 116
- 238000005160 1H NMR spectroscopy Methods 0.000 description 112
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 104
- 239000000243 solution Substances 0.000 description 78
- 235000019439 ethyl acetate Nutrition 0.000 description 75
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 71
- 125000006281 4-bromobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Br)C([H])([H])* 0.000 description 67
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 64
- 239000011734 sodium Substances 0.000 description 53
- 239000010410 layer Substances 0.000 description 51
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 48
- 239000011541 reaction mixture Substances 0.000 description 47
- 239000012267 brine Substances 0.000 description 46
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 46
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 44
- 239000012044 organic layer Substances 0.000 description 44
- 239000000047 product Substances 0.000 description 37
- 229960000583 acetic acid Drugs 0.000 description 36
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 30
- 238000010898 silica gel chromatography Methods 0.000 description 30
- 239000000706 filtrate Substances 0.000 description 27
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 25
- 239000002904 solvent Substances 0.000 description 25
- 150000004702 methyl esters Chemical class 0.000 description 22
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 22
- 238000006467 substitution reaction Methods 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 239000000725 suspension Substances 0.000 description 21
- 229910002651 NO3 Inorganic materials 0.000 description 20
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 20
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 20
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 18
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 18
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 18
- OIFCCGVSEGRJNL-UHFFFAOYSA-N 5-[4-[2-[(4-bromophenyl)methyl]-4-(2,4-dichlorophenyl)imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound ClC1=CC(Cl)=CC=C1C1=CN(C=2C=CC(=CC=2)N2S(NC(=O)C2)(=O)=O)C(CC=2C=CC(Br)=CC=2)=N1 OIFCCGVSEGRJNL-UHFFFAOYSA-N 0.000 description 17
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 17
- 230000002829 reductive effect Effects 0.000 description 17
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 16
- 239000003937 drug carrier Substances 0.000 description 16
- 239000000284 extract Substances 0.000 description 16
- IVLHRVBKAGAZSY-UHFFFAOYSA-N 5-[3-[2-[(4-bromophenyl)methyl]-4-(2,4-dichlorophenyl)imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound ClC1=CC(Cl)=CC=C1C1=CN(C=2C=C(C=CC=2)N2S(NC(=O)C2)(=O)=O)C(CC=2C=CC(Br)=CC=2)=N1 IVLHRVBKAGAZSY-UHFFFAOYSA-N 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 15
- 238000003756 stirring Methods 0.000 description 15
- 150000002148 esters Chemical class 0.000 description 14
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 13
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 13
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 12
- 238000005481 NMR spectroscopy Methods 0.000 description 12
- 239000012074 organic phase Substances 0.000 description 12
- KNQVRFYNQWNYPU-UHFFFAOYSA-N (4-cyclohexylphenyl)boronic acid Chemical compound C1=CC(B(O)O)=CC=C1C1CCCCC1 KNQVRFYNQWNYPU-UHFFFAOYSA-N 0.000 description 11
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 11
- QOWSWEBLNVACCL-UHFFFAOYSA-N 4-Bromophenyl acetate Chemical compound OC(=O)CC1=CC=C(Br)C=C1 QOWSWEBLNVACCL-UHFFFAOYSA-N 0.000 description 10
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- 239000004215 Carbon black (E152) Substances 0.000 description 9
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 9
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 9
- 125000001153 fluoro group Chemical group F* 0.000 description 9
- 229930195733 hydrocarbon Natural products 0.000 description 9
- WFQDTOYDVUWQMS-UHFFFAOYSA-N 1-fluoro-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C=C1 WFQDTOYDVUWQMS-UHFFFAOYSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 8
- 101001087394 Homo sapiens Tyrosine-protein phosphatase non-receptor type 1 Proteins 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 8
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 8
- 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- 150000001412 amines Chemical class 0.000 description 8
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 8
- 229910052794 bromium Inorganic materials 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 8
- MNJYZNVROSZZQC-UHFFFAOYSA-N (4-tert-butylphenyl)boronic acid Chemical compound CC(C)(C)C1=CC=C(B(O)O)C=C1 MNJYZNVROSZZQC-UHFFFAOYSA-N 0.000 description 7
- ZRYZBQLXDKPBDU-UHFFFAOYSA-N 4-bromobenzaldehyde Chemical compound BrC1=CC=C(C=O)C=C1 ZRYZBQLXDKPBDU-UHFFFAOYSA-N 0.000 description 7
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 7
- 230000029936 alkylation Effects 0.000 description 7
- 238000005804 alkylation reaction Methods 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- JSZAZZQHDRHICK-UHFFFAOYSA-N 1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical class O=C1CNS(=O)(=O)N1 JSZAZZQHDRHICK-UHFFFAOYSA-N 0.000 description 6
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 6
- DASJDMQCPIDJIF-UHFFFAOYSA-N 2-bromo-1-(2,4-dichlorophenyl)ethanone Chemical compound ClC1=CC=C(C(=O)CBr)C(Cl)=C1 DASJDMQCPIDJIF-UHFFFAOYSA-N 0.000 description 6
- 239000005711 Benzoic acid Substances 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000005859 coupling reaction Methods 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- 229940107698 malachite green Drugs 0.000 description 6
- FDZZZRQASAIRJF-UHFFFAOYSA-M malachite green Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](C)C)C=C1 FDZZZRQASAIRJF-UHFFFAOYSA-M 0.000 description 6
- YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 5
- ZEEPSBBAWJEOQY-UHFFFAOYSA-N 2-[(4-bromophenyl)methyl]-5-(2,4-dichlorophenyl)-1h-imidazole Chemical compound ClC1=CC(Cl)=CC=C1C1=CNC(CC=2C=CC(Br)=CC=2)=N1 ZEEPSBBAWJEOQY-UHFFFAOYSA-N 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 5
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 5
- 239000005695 Ammonium acetate Substances 0.000 description 5
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 5
- 208000008589 Obesity Diseases 0.000 description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 5
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 5
- 229940043376 ammonium acetate Drugs 0.000 description 5
- 235000019257 ammonium acetate Nutrition 0.000 description 5
- 150000001448 anilines Chemical class 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 239000007900 aqueous suspension Substances 0.000 description 5
- 150000001499 aryl bromides Chemical class 0.000 description 5
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000007859 condensation product Substances 0.000 description 5
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 5
- 239000002270 dispersing agent Substances 0.000 description 5
- 238000003818 flash chromatography Methods 0.000 description 5
- 235000013355 food flavoring agent Nutrition 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- VCBZMYOMQWTCKS-UHFFFAOYSA-N methyl 2-[4-[2-[(4-bromophenyl)methyl]-4-(2,4-dichlorophenyl)imidazol-1-yl]anilino]acetate Chemical compound C1=CC(NCC(=O)OC)=CC=C1N1C(CC=2C=CC(Br)=CC=2)=NC(C=2C(=CC(Cl)=CC=2)Cl)=C1 VCBZMYOMQWTCKS-UHFFFAOYSA-N 0.000 description 5
- 235000020824 obesity Nutrition 0.000 description 5
- 229910052700 potassium Inorganic materials 0.000 description 5
- 239000011591 potassium Substances 0.000 description 5
- 230000036515 potency Effects 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 239000003765 sweetening agent Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- GUSWJGOYDXFJSI-UHFFFAOYSA-N 3,6-dichloropyridazine Chemical compound ClC1=CC=C(Cl)N=N1 GUSWJGOYDXFJSI-UHFFFAOYSA-N 0.000 description 4
- YAYJTZWOFRNVJS-UHFFFAOYSA-N 3-[2-[(4-bromophenyl)methyl]-4-(2,4-dichlorophenyl)imidazol-1-yl]aniline Chemical compound NC1=CC=CC(N2C(=NC(=C2)C=2C(=CC(Cl)=CC=2)Cl)CC=2C=CC(Br)=CC=2)=C1 YAYJTZWOFRNVJS-UHFFFAOYSA-N 0.000 description 4
- AGQFHWCVQRLEDI-UHFFFAOYSA-N 5-[4-[2-[[4-(4-bromophenyl)phenyl]methyl]-4-(2,4-dichlorophenyl)imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound ClC1=CC(Cl)=CC=C1C1=CN(C=2C=CC(=CC=2)N2S(NC(=O)C2)(=O)=O)C(CC=2C=CC(=CC=2)C=2C=CC(Br)=CC=2)=N1 AGQFHWCVQRLEDI-UHFFFAOYSA-N 0.000 description 4
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 4
- 229910004373 HOAc Inorganic materials 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 4
- 201000004681 Psoriasis Diseases 0.000 description 4
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 125000004419 alkynylene group Chemical group 0.000 description 4
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 4
- 239000003435 antirheumatic agent Substances 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- KDPAWGWELVVRCH-UHFFFAOYSA-M bromoacetate Chemical compound [O-]C(=O)CBr KDPAWGWELVVRCH-UHFFFAOYSA-M 0.000 description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000002988 disease modifying antirheumatic drug Substances 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 4
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 4
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical compound NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- ZSKXYSCQDWAUCM-UHFFFAOYSA-N 1-(chloromethyl)-2-dodecylbenzene Chemical compound CCCCCCCCCCCCC1=CC=CC=C1CCl ZSKXYSCQDWAUCM-UHFFFAOYSA-N 0.000 description 3
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 3
- SIFIRKGTABHGQK-UHFFFAOYSA-N 2-[(4-bromophenyl)methyl]-4-(2,4-dichlorophenyl)-1-(4-nitrophenyl)imidazole Chemical compound C1=CC([N+](=O)[O-])=CC=C1N1C(CC=2C=CC(Br)=CC=2)=NC(C=2C(=CC(Cl)=CC=2)Cl)=C1 SIFIRKGTABHGQK-UHFFFAOYSA-N 0.000 description 3
- YQDBTSRWKYTFOQ-UHFFFAOYSA-N 2-[[4-(4-tert-butylphenyl)phenyl]methyl]-4-(2,4-dichlorophenyl)-1-(4-iodophenyl)imidazole Chemical compound C1=CC(C(C)(C)C)=CC=C1C(C=C1)=CC=C1CC1=NC(C=2C(=CC(Cl)=CC=2)Cl)=CN1C1=CC=C(I)C=C1 YQDBTSRWKYTFOQ-UHFFFAOYSA-N 0.000 description 3
- 125000006147 3,3-dimethylbutyl sulfonyl group Chemical group 0.000 description 3
- SUISZCALMBHJQX-UHFFFAOYSA-N 3-bromobenzaldehyde Chemical compound BrC1=CC=CC(C=O)=C1 SUISZCALMBHJQX-UHFFFAOYSA-N 0.000 description 3
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 3
- 125000006483 4-iodobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1I)C([H])([H])* 0.000 description 3
- SDIKNEGBDKSJJH-UHFFFAOYSA-N 5-[3-[2-[[4-(6-chloropyridazin-3-yl)phenyl]methyl]-4-(2,4-dichlorophenyl)imidazol-1-yl]phenyl]-1,1-dioxo-2-(2-trimethylsilylethoxymethyl)-1,2,5-thiadiazolidin-3-one Chemical compound O=S1(=O)N(COCC[Si](C)(C)C)C(=O)CN1C1=CC=CC(N2C(=NC(=C2)C=2C(=CC(Cl)=CC=2)Cl)CC=2C=CC(=CC=2)C=2N=NC(Cl)=CC=2)=C1 SDIKNEGBDKSJJH-UHFFFAOYSA-N 0.000 description 3
- RNLJJRIMAAXDKB-UHFFFAOYSA-N 5-[3-[2-[[4-[3-(cyclohexylmethylsulfonyl)phenyl]phenyl]methyl]-4-(2,4-dichlorophenyl)imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound ClC1=CC(Cl)=CC=C1C1=CN(C=2C=C(C=CC=2)N2S(NC(=O)C2)(=O)=O)C(CC=2C=CC(=CC=2)C=2C=C(C=CC=2)S(=O)(=O)CC2CCCCC2)=N1 RNLJJRIMAAXDKB-UHFFFAOYSA-N 0.000 description 3
- WQCYRBPCQQVFHZ-UHFFFAOYSA-N 5-[3-[4-(2,4-difluorophenyl)-2-[[4-[3-(3,3-dimethylbutylsulfonyl)phenyl]phenyl]methyl]imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound CC(C)(C)CCS(=O)(=O)C1=CC=CC(C=2C=CC(CC=3N(C=C(N=3)C=3C(=CC(F)=CC=3)F)C=3C=C(C=CC=3)N3S(NC(=O)C3)(=O)=O)=CC=2)=C1 WQCYRBPCQQVFHZ-UHFFFAOYSA-N 0.000 description 3
- LGUFRVWOAYWKFU-UHFFFAOYSA-N 5-[4-[2-[(4-bromophenyl)methyl]-4-(2,4-difluorophenyl)imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound FC1=CC(F)=CC=C1C1=CN(C=2C=CC(=CC=2)N2S(NC(=O)C2)(=O)=O)C(CC=2C=CC(Br)=CC=2)=N1 LGUFRVWOAYWKFU-UHFFFAOYSA-N 0.000 description 3
- GPPBLOAURZTOCB-UHFFFAOYSA-N 5-[4-[2-[[4-(4-aminophenyl)phenyl]methyl]-4-(2,4-dichlorophenyl)imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound C1=CC(N)=CC=C1C(C=C1)=CC=C1CC1=NC(C=2C(=CC(Cl)=CC=2)Cl)=CN1C1=CC=C(N2S(NC(=O)C2)(=O)=O)C=C1 GPPBLOAURZTOCB-UHFFFAOYSA-N 0.000 description 3
- BZVDOYOGMWGQTE-UHFFFAOYSA-N 5-[4-[2-[[4-(6-chloropyridin-3-yl)phenyl]methyl]-4-(2,4-dichlorophenyl)imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound ClC1=CC(Cl)=CC=C1C1=CN(C=2C=CC(=CC=2)N2S(NC(=O)C2)(=O)=O)C(CC=2C=CC(=CC=2)C=2C=NC(Cl)=CC=2)=N1 BZVDOYOGMWGQTE-UHFFFAOYSA-N 0.000 description 3
- ZCYUIAXGFAREEJ-UHFFFAOYSA-N 5-[4-[4-(2,4-dichlorophenyl)-2-[[4-[4-(3-oxopiperazin-1-yl)phenyl]phenyl]methyl]imidazol-1-yl]phenyl]-1,1-dioxo-2-(2-trimethylsilylethoxymethyl)-1,2,5-thiadiazolidin-3-one Chemical compound O=S1(=O)N(COCC[Si](C)(C)C)C(=O)CN1C1=CC=C(N2C(=NC(=C2)C=2C(=CC(Cl)=CC=2)Cl)CC=2C=CC(=CC=2)C=2C=CC(=CC=2)N2CC(=O)NCC2)C=C1 ZCYUIAXGFAREEJ-UHFFFAOYSA-N 0.000 description 3
- AMKGKYQBASDDJB-UHFFFAOYSA-N 9$l^{2}-borabicyclo[3.3.1]nonane Chemical compound C1CCC2CCCC1[B]2 AMKGKYQBASDDJB-UHFFFAOYSA-N 0.000 description 3
- FEJUGLKDZJDVFY-UHFFFAOYSA-N 9-borabicyclo[3.3.1]nonane Substances C1CCC2CCCC1B2 FEJUGLKDZJDVFY-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 235000019483 Peanut oil Nutrition 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000006069 Suzuki reaction reaction Methods 0.000 description 3
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 3
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 3
- 101710098414 Tyrosine-protein phosphatase Proteins 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 125000005137 alkenylsulfonyl group Chemical group 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 125000005139 alkynylsulfonyl group Chemical group 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 150000008064 anhydrides Chemical class 0.000 description 3
- 230000005784 autoimmunity Effects 0.000 description 3
- 229910052788 barium Inorganic materials 0.000 description 3
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- FCYRSDMGOLYDHL-UHFFFAOYSA-N chloromethoxyethane Chemical compound CCOCCl FCYRSDMGOLYDHL-UHFFFAOYSA-N 0.000 description 3
- WRJWRGBVPUUDLA-UHFFFAOYSA-N chlorosulfonyl isocyanate Chemical compound ClS(=O)(=O)N=C=O WRJWRGBVPUUDLA-UHFFFAOYSA-N 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 125000004494 ethyl ester group Chemical group 0.000 description 3
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 3
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 150000002430 hydrocarbons Chemical class 0.000 description 3
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 3
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- PEMGGJDINLGTON-UHFFFAOYSA-N n-(3-aminophenyl)acetamide Chemical compound CC(=O)NC1=CC=CC(N)=C1 PEMGGJDINLGTON-UHFFFAOYSA-N 0.000 description 3
- 150000002828 nitro derivatives Chemical class 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 239000000312 peanut oil Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 150000003511 tertiary amides Chemical class 0.000 description 3
- 150000003573 thiols Chemical class 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 238000009736 wetting Methods 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- QBLFZIBJXUQVRF-UHFFFAOYSA-N (4-bromophenyl)boronic acid Chemical compound OB(O)C1=CC=C(Br)C=C1 QBLFZIBJXUQVRF-UHFFFAOYSA-N 0.000 description 2
- CHSPURIZKQPJNH-UHFFFAOYSA-N (4-butan-2-ylphenyl)boronic acid Chemical compound CCC(C)C1=CC=C(B(O)O)C=C1 CHSPURIZKQPJNH-UHFFFAOYSA-N 0.000 description 2
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
- DAGWHFUEMCYDES-UHFFFAOYSA-N 1-[(4-bromophenyl)methyl]-4-(2,4-dichlorophenyl)-2-(4-nitrophenyl)imidazole Chemical compound C1=CC([N+](=O)[O-])=CC=C1C1=NC(C=2C(=CC(Cl)=CC=2)Cl)=CN1CC1=CC=C(Br)C=C1 DAGWHFUEMCYDES-UHFFFAOYSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- MIIWJRWWDMGVCS-UHFFFAOYSA-N 1-cyclohexyl-4-[4-[[4-(2,4-dichlorophenyl)-1-(4-nitrophenyl)imidazol-2-yl]methyl]phenyl]pyridin-2-one Chemical compound C1=CC([N+](=O)[O-])=CC=C1N1C(CC=2C=CC(=CC=2)C2=CC(=O)N(C3CCCCC3)C=C2)=NC(C=2C(=CC(Cl)=CC=2)Cl)=C1 MIIWJRWWDMGVCS-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- HHKSCYDRLCQYGH-UHFFFAOYSA-N 2-[(4-bromophenyl)methyl]-4-(4-methylsulfonylphenyl)-1-(4-nitrophenyl)imidazole Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CN(C=2C=CC(=CC=2)[N+]([O-])=O)C(CC=2C=CC(Br)=CC=2)=N1 HHKSCYDRLCQYGH-UHFFFAOYSA-N 0.000 description 2
- RCMCHBPSKFVADT-UHFFFAOYSA-N 2-[[2-[4-(4-tert-butylphenyl)phenyl]-4-(2,4-dichlorophenyl)-5-(4-nitrophenyl)imidazol-1-yl]methoxy]ethyl-trimethylsilane Chemical compound C1=CC(C(C)(C)C)=CC=C1C1=CC=C(C=2N(C(C=3C=CC(=CC=3)[N+]([O-])=O)=C(N=2)C=2C(=CC(Cl)=CC=2)Cl)COCC[Si](C)(C)C)C=C1 RCMCHBPSKFVADT-UHFFFAOYSA-N 0.000 description 2
- NVHLCYLXMBXFJS-UHFFFAOYSA-N 2-bromothiadiazolidin-4-one Chemical compound BrN1NC(=O)CS1 NVHLCYLXMBXFJS-UHFFFAOYSA-N 0.000 description 2
- QJQZRLXDLORINA-UHFFFAOYSA-N 2-cyclohexylethanol Chemical compound OCCC1CCCCC1 QJQZRLXDLORINA-UHFFFAOYSA-N 0.000 description 2
- VVAAJAZKTLEWFQ-UHFFFAOYSA-N 2-cyclopentyl-1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethanol Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(C(O)CC2CCCC2)C=C1 VVAAJAZKTLEWFQ-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- GTZWARVSWYDNMS-UHFFFAOYSA-N 2-tert-butyl-5-[3-[[2-(2,4-dichlorophenyl)-2-oxoethyl]amino]phenyl]-1,1-dioxo-1,2-thiazol-3-one Chemical compound O=S1(=O)N(C(C)(C)C)C(=O)C=C1C1=CC=CC(NCC(=O)C=2C(=CC(Cl)=CC=2)Cl)=C1 GTZWARVSWYDNMS-UHFFFAOYSA-N 0.000 description 2
- XJCVRTZCHMZPBD-UHFFFAOYSA-N 3-nitroaniline Chemical compound NC1=CC=CC([N+]([O-])=O)=C1 XJCVRTZCHMZPBD-UHFFFAOYSA-N 0.000 description 2
- PIKZZSMPNZFUJP-UHFFFAOYSA-N 4-(2,4-dichlorophenyl)-2-[(6-methoxynaphthalen-2-yl)methyl]-1-(4-nitrophenyl)imidazole Chemical compound C1=CC2=CC(OC)=CC=C2C=C1CC1=NC(C=2C(=CC(Cl)=CC=2)Cl)=CN1C1=CC=C([N+]([O-])=O)C=C1 PIKZZSMPNZFUJP-UHFFFAOYSA-N 0.000 description 2
- VOLRSQPSJGXRNJ-UHFFFAOYSA-N 4-nitrobenzyl bromide Chemical compound [O-][N+](=O)C1=CC=C(CBr)C=C1 VOLRSQPSJGXRNJ-UHFFFAOYSA-N 0.000 description 2
- ZZUUQQGVTDUXPN-UHFFFAOYSA-N 5-(2,4-dichlorophenyl)-2-[(4-iodophenyl)methyl]-1h-imidazole Chemical compound ClC1=CC(Cl)=CC=C1C1=CNC(CC=2C=CC(I)=CC=2)=N1 ZZUUQQGVTDUXPN-UHFFFAOYSA-N 0.000 description 2
- XQRFGBXLKAGSSL-UHFFFAOYSA-N 5-(3-aminophenyl)-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound NC1=CC=CC(N2S(NC(=O)C2)(=O)=O)=C1 XQRFGBXLKAGSSL-UHFFFAOYSA-N 0.000 description 2
- DPPHMWQGFPIPLG-UHFFFAOYSA-N 5-(3-aminophenyl)-2-tert-butyl-1,1-dioxo-1,2-thiazol-3-one Chemical compound O=S1(=O)N(C(C)(C)C)C(=O)C=C1C1=CC=CC(N)=C1 DPPHMWQGFPIPLG-UHFFFAOYSA-N 0.000 description 2
- NCQORJKTWWASCL-UHFFFAOYSA-N 5-[3-[2-[(4-bromophenyl)methyl]-4-(2,4-dichlorophenyl)imidazol-1-yl]phenyl]-2-tert-butyl-1,1-dioxo-1,2-thiazol-3-one Chemical compound O=S1(=O)N(C(C)(C)C)C(=O)C=C1C1=CC=CC(N2C(=NC(=C2)C=2C(=CC(Cl)=CC=2)Cl)CC=2C=CC(Br)=CC=2)=C1 NCQORJKTWWASCL-UHFFFAOYSA-N 0.000 description 2
- RLKWZALDOHVUHA-UHFFFAOYSA-N 5-[3-[2-[[4-(4-aminophenyl)phenyl]methyl]-4-(2,4-dichlorophenyl)imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound C1=CC(N)=CC=C1C(C=C1)=CC=C1CC1=NC(C=2C(=CC(Cl)=CC=2)Cl)=CN1C1=CC=CC(N2S(NC(=O)C2)(=O)=O)=C1 RLKWZALDOHVUHA-UHFFFAOYSA-N 0.000 description 2
- MNBXBJAJICXVLF-UHFFFAOYSA-N 5-[3-[2-[[4-[6-(cyclohexylmethoxy)pyridazin-3-yl]phenyl]methyl]-4-(2,4-dichlorophenyl)imidazol-1-yl]phenyl]-1,1-dioxo-2-(2-trimethylsilylethoxymethyl)-1,2,5-thiadiazolidin-3-one Chemical compound O=S1(=O)N(COCC[Si](C)(C)C)C(=O)CN1C1=CC=CC(N2C(=NC(=C2)C=2C(=CC(Cl)=CC=2)Cl)CC=2C=CC(=CC=2)C=2N=NC(OCC3CCCCC3)=CC=2)=C1 MNBXBJAJICXVLF-UHFFFAOYSA-N 0.000 description 2
- BHRVRCUAQMSZBF-UHFFFAOYSA-N 5-[3-[4-(2,4-dichlorophenyl)-2-[[4-[3-(3,3-dimethylbutylsulfonyl)phenyl]phenyl]methyl]imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound CC(C)(C)CCS(=O)(=O)C1=CC=CC(C=2C=CC(CC=3N(C=C(N=3)C=3C(=CC(Cl)=CC=3)Cl)C=3C=C(C=CC=3)N3S(NC(=O)C3)(=O)=O)=CC=2)=C1 BHRVRCUAQMSZBF-UHFFFAOYSA-N 0.000 description 2
- SGGCRUGHYRGJOR-UHFFFAOYSA-N 5-[4-[2-[(4-bromophenyl)methyl]-4-(2,4-dichlorophenyl)imidazol-1-yl]phenyl]-1,1-dioxo-2-(2-trimethylsilylethoxymethyl)-1,2,5-thiadiazolidin-3-one Chemical compound O=S1(=O)N(COCC[Si](C)(C)C)C(=O)CN1C1=CC=C(N2C(=NC(=C2)C=2C(=CC(Cl)=CC=2)Cl)CC=2C=CC(Br)=CC=2)C=C1 SGGCRUGHYRGJOR-UHFFFAOYSA-N 0.000 description 2
- BVEYPWHFVJFWTN-UHFFFAOYSA-N 5-[4-[2-[[4-(4-aminophenyl)phenyl]methyl]-4-(2,4-dichlorophenyl)imidazol-1-yl]phenyl]-1,1-dioxo-2-(2-trimethylsilylethoxymethyl)-1,2,5-thiadiazolidin-3-one Chemical compound O=S1(=O)N(COCC[Si](C)(C)C)C(=O)CN1C1=CC=C(N2C(=NC(=C2)C=2C(=CC(Cl)=CC=2)Cl)CC=2C=CC(=CC=2)C=2C=CC(N)=CC=2)C=C1 BVEYPWHFVJFWTN-UHFFFAOYSA-N 0.000 description 2
- PYQOXHQHXOTUQK-UHFFFAOYSA-N 5-[4-[2-[[4-[3-amino-4-(2-methylpropyl)phenyl]phenyl]methyl]-4-(2,4-dichlorophenyl)imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound C1=C(N)C(CC(C)C)=CC=C1C(C=C1)=CC=C1CC1=NC(C=2C(=CC(Cl)=CC=2)Cl)=CN1C1=CC=C(N2S(NC(=O)C2)(=O)=O)C=C1 PYQOXHQHXOTUQK-UHFFFAOYSA-N 0.000 description 2
- WFASDUHXTJNFJW-UHFFFAOYSA-N 5-[4-[4-(2,4-dichlorophenyl)-2-[[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl]imidazol-1-yl]phenyl]-1,1-dioxo-2-(2-trimethylsilylethoxymethyl)-1,2,5-thiadiazolidin-3-one Chemical compound O1C(C)(C)C(C)(C)OB1C(C=C1)=CC=C1CC1=NC(C=2C(=CC(Cl)=CC=2)Cl)=CN1C1=CC=C(N2S(N(COCC[Si](C)(C)C)C(=O)C2)(=O)=O)C=C1 WFASDUHXTJNFJW-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical compound CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 2
- 108010001441 Phosphopeptides Proteins 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 241001582429 Tetracis Species 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- JOKAVGQOOAUGSH-UHFFFAOYSA-N [3-(2-cyclohexylethoxy)phenyl]boronic acid Chemical compound OB(O)C1=CC=CC(OCCC2CCCCC2)=C1 JOKAVGQOOAUGSH-UHFFFAOYSA-N 0.000 description 2
- CPGZRYJEHQGLOY-UHFFFAOYSA-N [3-(3,3-dimethylbutoxy)phenyl]boronic acid Chemical compound CC(C)(C)CCOC1=CC=CC(B(O)O)=C1 CPGZRYJEHQGLOY-UHFFFAOYSA-N 0.000 description 2
- ZHUOZJWREXWGNF-UHFFFAOYSA-N [4-(4,4-dimethylpentyl)phenyl]boronic acid Chemical compound CC(C)(C)CCCC1=CC=C(B(O)O)C=C1 ZHUOZJWREXWGNF-UHFFFAOYSA-N 0.000 description 2
- KXOJKGOXRZMOBU-UHFFFAOYSA-N [4-(cyclohexylmethoxy)phenyl]boronic acid Chemical compound C1=CC(B(O)O)=CC=C1OCC1CCCCC1 KXOJKGOXRZMOBU-UHFFFAOYSA-N 0.000 description 2
- NOUPSWIVVJVDMH-UHFFFAOYSA-M [Cl-].CC(C)(C)CC[Mg+] Chemical compound [Cl-].CC(C)(C)CC[Mg+] NOUPSWIVVJVDMH-UHFFFAOYSA-M 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000000048 adrenergic agonist Substances 0.000 description 2
- ILOJFJBXXANEQW-UHFFFAOYSA-N aminooxy(phenyl)borinic acid Chemical compound NOB(O)C1=CC=CC=C1 ILOJFJBXXANEQW-UHFFFAOYSA-N 0.000 description 2
- 239000011609 ammonium molybdate Substances 0.000 description 2
- 235000018660 ammonium molybdate Nutrition 0.000 description 2
- APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 description 2
- 229940010552 ammonium molybdate Drugs 0.000 description 2
- 229940025084 amphetamine Drugs 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000000883 anti-obesity agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940125710 antiobesity agent Drugs 0.000 description 2
- 229940127218 antiplatelet drug Drugs 0.000 description 2
- 239000000164 antipsychotic agent Substances 0.000 description 2
- 229940005529 antipsychotics Drugs 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 239000002830 appetite depressant Substances 0.000 description 2
- 125000000732 arylene group Chemical group 0.000 description 2
- 239000000305 astragalus gummifer gum Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 150000001555 benzenes Chemical group 0.000 description 2
- 150000004283 biguanides Chemical class 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 150000001642 boronic acid derivatives Chemical class 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
- 238000007872 degassing Methods 0.000 description 2
- 230000030609 dephosphorylation Effects 0.000 description 2
- 238000006209 dephosphorylation reaction Methods 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 2
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
- IIEWJVIFRVWJOD-UHFFFAOYSA-N ethyl cyclohexane Natural products CCC1CCCCC1 IIEWJVIFRVWJOD-UHFFFAOYSA-N 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 229960004580 glibenclamide Drugs 0.000 description 2
- 229960001381 glipizide Drugs 0.000 description 2
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 125000005549 heteroarylene group Chemical group 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 239000000367 immunologic factor Substances 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- WGOPGODQLGJZGL-UHFFFAOYSA-N lithium;butane Chemical compound [Li+].CC[CH-]C WGOPGODQLGJZGL-UHFFFAOYSA-N 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 229910001623 magnesium bromide Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- FYSBDPODOKCGKN-UHFFFAOYSA-N methyl 2-(3-nitroanilino)acetate Chemical compound COC(=O)CNC1=CC=CC([N+]([O-])=O)=C1 FYSBDPODOKCGKN-UHFFFAOYSA-N 0.000 description 2
- NKNASKIKBCDNHM-UHFFFAOYSA-N methyl 2-[4-[4-(2,4-dichlorophenyl)-2-[(6-methoxynaphthalen-2-yl)methyl]imidazol-1-yl]anilino]acetate Chemical compound C1=CC(NCC(=O)OC)=CC=C1N1C(CC=2C=C3C=CC(OC)=CC3=CC=2)=NC(C=2C(=CC(Cl)=CC=2)Cl)=C1 NKNASKIKBCDNHM-UHFFFAOYSA-N 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- LFLZOWIFJOBEPN-UHFFFAOYSA-N nitrate, nitrate Chemical compound O[N+]([O-])=O.O[N+]([O-])=O LFLZOWIFJOBEPN-UHFFFAOYSA-N 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 230000000269 nucleophilic effect Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000012053 oil suspension Substances 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 2
- 229960001243 orlistat Drugs 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 description 2
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 229960003562 phentermine Drugs 0.000 description 2
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 2
- 229960000395 phenylpropanolamine Drugs 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical compound O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 description 2
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 235000015320 potassium carbonate Nutrition 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000009822 protein phosphorylation Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- JZCPYUJPEARBJL-UHFFFAOYSA-N rimonabant Chemical compound CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 description 2
- 229960003015 rimonabant Drugs 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 229960004425 sibutramine Drugs 0.000 description 2
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000010269 sulphur dioxide Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 108090000721 thyroid hormone receptors Proteins 0.000 description 2
- 102000004217 thyroid hormone receptors Human genes 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 229960004394 topiramate Drugs 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 229940086542 triethylamine Drugs 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 239000002691 unilamellar liposome Substances 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- YDMRDHQUQIVWBE-UHFFFAOYSA-N (2-hydroxyphenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1O YDMRDHQUQIVWBE-UHFFFAOYSA-N 0.000 description 1
- ICRHNMKDEVGGGH-UHFFFAOYSA-N (2-morpholin-4-ylphenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1N1CCOCC1 ICRHNMKDEVGGGH-UHFFFAOYSA-N 0.000 description 1
- RADLTTWFPYPHIV-UHFFFAOYSA-N (2-sulfanylphenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1S RADLTTWFPYPHIV-UHFFFAOYSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- QBEMGQXOYHCGLL-XIFFEERXSA-N (2s)-2-[4-[2-[[4-(4-tert-butylphenyl)phenyl]methyl]-4-(2,4-dichlorophenyl)imidazol-1-yl]anilino]pentanoic acid Chemical compound C1=CC(N[C@@H](CCC)C(O)=O)=CC=C1N1C(CC=2C=CC(=CC=2)C=2C=CC(=CC=2)C(C)(C)C)=NC(C=2C(=CC(Cl)=CC=2)Cl)=C1 QBEMGQXOYHCGLL-XIFFEERXSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- QBKWMNFYLXBEDV-UHFFFAOYSA-N (3-chloropyridin-2-yl)boronic acid Chemical compound OB(O)C1=NC=CC=C1Cl QBKWMNFYLXBEDV-UHFFFAOYSA-N 0.000 description 1
- WFWQWTPAPNEOFE-UHFFFAOYSA-N (3-hydroxyphenyl)boronic acid Chemical compound OB(O)C1=CC=CC(O)=C1 WFWQWTPAPNEOFE-UHFFFAOYSA-N 0.000 description 1
- QSWLFBMVIGQONC-UHFFFAOYSA-N (3-propan-2-ylphenyl)boronic acid Chemical compound CC(C)C1=CC=CC(B(O)O)=C1 QSWLFBMVIGQONC-UHFFFAOYSA-N 0.000 description 1
- SRSWMXFANVKOFH-UHFFFAOYSA-N (3-propoxyphenyl)boronic acid Chemical compound CCCOC1=CC=CC(B(O)O)=C1 SRSWMXFANVKOFH-UHFFFAOYSA-N 0.000 description 1
- OQANPHBRHBJGNZ-FYJGNVAPSA-N (3e)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=C\C1=N\NC1=CC=C(S(=O)(=O)NC=2N=CC=CC=2)C=C1 OQANPHBRHBJGNZ-FYJGNVAPSA-N 0.000 description 1
- MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 1
- PRRFFTYUBPGHLE-SNVBAGLBSA-N (3s)-3-phenylpyrrolidine Chemical compound C1NCC[C@H]1C1=CC=CC=C1 PRRFFTYUBPGHLE-SNVBAGLBSA-N 0.000 description 1
- UGZUUTHZEATQAM-UHFFFAOYSA-N (4-butylphenyl)boronic acid Chemical compound CCCCC1=CC=C(B(O)O)C=C1 UGZUUTHZEATQAM-UHFFFAOYSA-N 0.000 description 1
- CXQWADWZIYSSDJ-UHFFFAOYSA-N (4-cyclopentylphenyl)boronic acid Chemical compound C1=CC(B(O)O)=CC=C1C1CCCC1 CXQWADWZIYSSDJ-UHFFFAOYSA-N 0.000 description 1
- ZLNFACCFYUFTLD-UHFFFAOYSA-N (4-ethoxycarbonylphenyl)boronic acid Chemical compound CCOC(=O)C1=CC=C(B(O)O)C=C1 ZLNFACCFYUFTLD-UHFFFAOYSA-N 0.000 description 1
- COIQUVGFTILYGA-UHFFFAOYSA-N (4-hydroxyphenyl)boronic acid Chemical compound OB(O)C1=CC=C(O)C=C1 COIQUVGFTILYGA-UHFFFAOYSA-N 0.000 description 1
- KFXUHRXGLWUOJT-UHFFFAOYSA-N (4-phenoxyphenyl)boronic acid Chemical compound C1=CC(B(O)O)=CC=C1OC1=CC=CC=C1 KFXUHRXGLWUOJT-UHFFFAOYSA-N 0.000 description 1
- SUXBGJJJOLDLKL-UHFFFAOYSA-N (4-propanoylphenyl)boronic acid Chemical compound CCC(=O)C1=CC=C(B(O)O)C=C1 SUXBGJJJOLDLKL-UHFFFAOYSA-N 0.000 description 1
- SOKFEJKZYHYKSY-UHFFFAOYSA-N (4-propoxyphenyl)boronic acid Chemical compound CCCOC1=CC=C(B(O)O)C=C1 SOKFEJKZYHYKSY-UHFFFAOYSA-N 0.000 description 1
- WLCGYIWOKVWFLB-UHFFFAOYSA-N (4-propylphenyl)boronic acid Chemical compound CCCC1=CC=C(B(O)O)C=C1 WLCGYIWOKVWFLB-UHFFFAOYSA-N 0.000 description 1
- WPAPNCXMYWRTTL-UHFFFAOYSA-N (6-chloropyridin-3-yl)boronic acid Chemical compound OB(O)C1=CC=C(Cl)N=C1 WPAPNCXMYWRTTL-UHFFFAOYSA-N 0.000 description 1
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 description 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- ZGYIXVSQHOKQRZ-COIATFDQSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-[(3s)-oxolan-3-yl]oxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N#CC1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZGYIXVSQHOKQRZ-COIATFDQSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- HOPFEDLIYBPKII-UHFFFAOYSA-N 1,2,5-thiadiazolidin-3-one Chemical compound O=C1CNSN1 HOPFEDLIYBPKII-UHFFFAOYSA-N 0.000 description 1
- VDFVNEFVBPFDSB-UHFFFAOYSA-N 1,3-dioxane Chemical compound C1COCOC1 VDFVNEFVBPFDSB-UHFFFAOYSA-N 0.000 description 1
- LFMWZTSOMGDDJU-UHFFFAOYSA-N 1,4-diiodobenzene Chemical compound IC1=CC=C(I)C=C1 LFMWZTSOMGDDJU-UHFFFAOYSA-N 0.000 description 1
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- HLVFKOKELQSXIQ-UHFFFAOYSA-N 1-bromo-2-methylpropane Chemical compound CC(C)CBr HLVFKOKELQSXIQ-UHFFFAOYSA-N 0.000 description 1
- YLRBJYMANQKEAW-UHFFFAOYSA-N 1-bromo-4-(bromomethyl)benzene Chemical compound BrCC1=CC=C(Br)C=C1 YLRBJYMANQKEAW-UHFFFAOYSA-N 0.000 description 1
- XUCYJGMIICONES-UHFFFAOYSA-N 1-fluoro-2-methyl-4-nitrobenzene Chemical compound CC1=CC([N+]([O-])=O)=CC=C1F XUCYJGMIICONES-UHFFFAOYSA-N 0.000 description 1
- CBYAZOKPJYBCHE-UHFFFAOYSA-N 1-iodo-3-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC(I)=C1 CBYAZOKPJYBCHE-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- YRAJNWYBUCUFBD-UHFFFAOYSA-N 2,2,6,6-tetramethylheptane-3,5-dione Chemical compound CC(C)(C)C(=O)CC(=O)C(C)(C)C YRAJNWYBUCUFBD-UHFFFAOYSA-N 0.000 description 1
- AFQYFVWMIRMBAE-UHFFFAOYSA-N 2,2-dimethylpropyl carbamate Chemical group CC(C)(C)COC(N)=O AFQYFVWMIRMBAE-UHFFFAOYSA-N 0.000 description 1
- JUUBFHLPTCPVBO-UHFFFAOYSA-N 2,2-dimethylpropyl carbonochloridate Chemical compound CC(C)(C)COC(Cl)=O JUUBFHLPTCPVBO-UHFFFAOYSA-N 0.000 description 1
- RPVJWGJEXCSQIY-UHFFFAOYSA-N 2,2-dimethylpropyl piperazine-1-carboxylate Chemical compound CC(C)(C)COC(=O)N1CCNCC1 RPVJWGJEXCSQIY-UHFFFAOYSA-N 0.000 description 1
- ZHXUWDPHUQHFOV-UHFFFAOYSA-N 2,5-dibromopyridine Chemical compound BrC1=CC=C(Br)N=C1 ZHXUWDPHUQHFOV-UHFFFAOYSA-N 0.000 description 1
- VQVBNWUUKLBHGI-UHFFFAOYSA-N 2-(4-bromophenyl)acetyl chloride Chemical compound ClC(=O)CC1=CC=C(Br)C=C1 VQVBNWUUKLBHGI-UHFFFAOYSA-N 0.000 description 1
- LOWWSYWGAKCKLG-UHFFFAOYSA-N 2-(6-methoxynaphthalen-1-yl)acetic acid Chemical compound OC(=O)CC1=CC=CC2=CC(OC)=CC=C21 LOWWSYWGAKCKLG-UHFFFAOYSA-N 0.000 description 1
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 1
- IACQESXIONNKCQ-UHFFFAOYSA-N 2-[(4-bromophenyl)methyl]-1-(4-nitrophenyl)-4-[4-(trifluoromethyl)phenyl]imidazole Chemical compound C1=CC([N+](=O)[O-])=CC=C1N1C(CC=2C=CC(Br)=CC=2)=NC(C=2C=CC(=CC=2)C(F)(F)F)=C1 IACQESXIONNKCQ-UHFFFAOYSA-N 0.000 description 1
- FMYAERKEPXTYIL-UHFFFAOYSA-N 2-[(4-bromophenyl)methyl]-4-(2,4-dichlorophenyl)-1-(3-methyl-4-nitrophenyl)imidazole Chemical compound C1=C([N+]([O-])=O)C(C)=CC(N2C(=NC(=C2)C=2C(=CC(Cl)=CC=2)Cl)CC=2C=CC(Br)=CC=2)=C1 FMYAERKEPXTYIL-UHFFFAOYSA-N 0.000 description 1
- QZXBBDVUNMWWHL-UHFFFAOYSA-N 2-[(4-bromophenyl)methyl]-4-(2,4-dichlorophenyl)-1-[(4-nitrophenyl)methyl]imidazole Chemical compound C1=CC([N+](=O)[O-])=CC=C1CN1C(CC=2C=CC(Br)=CC=2)=NC(C=2C(=CC(Cl)=CC=2)Cl)=C1 QZXBBDVUNMWWHL-UHFFFAOYSA-N 0.000 description 1
- SZQOWNXZMMALRD-UHFFFAOYSA-N 2-[(4-bromophenyl)methyl]-4-(2,4-dichlorophenyl)-1-[2-(3-nitrophenyl)phenyl]imidazole Chemical compound [O-][N+](=O)C1=CC=CC(C=2C(=CC=CC=2)N2C(=NC(=C2)C=2C(=CC(Cl)=CC=2)Cl)CC=2C=CC(Br)=CC=2)=C1 SZQOWNXZMMALRD-UHFFFAOYSA-N 0.000 description 1
- ZHRFDLIWSHTGPU-UHFFFAOYSA-N 2-[(4-bromophenyl)methyl]-4-(2,6-dichlorophenyl)-1-(4-nitrophenyl)imidazole Chemical compound C1=CC([N+](=O)[O-])=CC=C1N1C(CC=2C=CC(Br)=CC=2)=NC(C=2C(=CC=CC=2Cl)Cl)=C1 ZHRFDLIWSHTGPU-UHFFFAOYSA-N 0.000 description 1
- QXMYBJLLZZDWFN-UHFFFAOYSA-N 2-[(4-bromophenyl)methyl]-5-(4-methylsulfonylphenyl)-1h-imidazole Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CNC(CC=2C=CC(Br)=CC=2)=N1 QXMYBJLLZZDWFN-UHFFFAOYSA-N 0.000 description 1
- YQNRVGJCPCNMKT-LFVJCYFKSA-N 2-[(e)-[[2-(4-benzylpiperazin-1-ium-1-yl)acetyl]hydrazinylidene]methyl]-6-prop-2-enylphenolate Chemical compound [O-]C1=C(CC=C)C=CC=C1\C=N\NC(=O)C[NH+]1CCN(CC=2C=CC=CC=2)CC1 YQNRVGJCPCNMKT-LFVJCYFKSA-N 0.000 description 1
- AOSJUUNRJNQYBH-UHFFFAOYSA-N 2-[4-(4-cyclohexylphenyl)phenyl]acetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1C1=CC=C(C2CCCCC2)C=C1 AOSJUUNRJNQYBH-UHFFFAOYSA-N 0.000 description 1
- MXGJWJYKXNUQEP-UHFFFAOYSA-N 2-[[2-[[4-(4-tert-butylphenyl)phenyl]methyl]-4-(2,4-dichlorophenyl)-5-(4-nitrophenyl)imidazol-1-yl]methoxy]ethyl-trimethylsilane Chemical compound C1=CC(C(C)(C)C)=CC=C1C(C=C1)=CC=C1CC(N1COCC[Si](C)(C)C)=NC(C=2C(=CC(Cl)=CC=2)Cl)=C1C1=CC=C([N+]([O-])=O)C=C1 MXGJWJYKXNUQEP-UHFFFAOYSA-N 0.000 description 1
- KEMJYQUBCUCNQQ-UHFFFAOYSA-N 2-[[4-(4-cyclohexylphenyl)phenyl]methyl]-4-(2,4-dichlorophenyl)-1-(2-methyl-4-nitrophenyl)imidazole Chemical compound CC1=CC([N+]([O-])=O)=CC=C1N1C(CC=2C=CC(=CC=2)C=2C=CC(=CC=2)C2CCCCC2)=NC(C=2C(=CC(Cl)=CC=2)Cl)=C1 KEMJYQUBCUCNQQ-UHFFFAOYSA-N 0.000 description 1
- HBVXZTUVPVPPAX-UHFFFAOYSA-N 2-[[4-(4-cyclohexylphenyl)phenyl]methyl]-5-(2,4-dichlorophenyl)-1h-imidazole Chemical compound ClC1=CC(Cl)=CC=C1C1=CNC(CC=2C=CC(=CC=2)C=2C=CC(=CC=2)C2CCCCC2)=N1 HBVXZTUVPVPPAX-UHFFFAOYSA-N 0.000 description 1
- HEQOJEGTZCTHCF-UHFFFAOYSA-N 2-amino-1-phenylethanone Chemical compound NCC(=O)C1=CC=CC=C1 HEQOJEGTZCTHCF-UHFFFAOYSA-N 0.000 description 1
- QRKJNCRCYBKANP-UHFFFAOYSA-N 2-amino-n-phenylacetamide Chemical compound NCC(=O)NC1=CC=CC=C1 QRKJNCRCYBKANP-UHFFFAOYSA-N 0.000 description 1
- HTFXWAOSQODIBI-UHFFFAOYSA-N 2-benzyl-1,3-dihydropyrrolo[3,4-c]pyridine Chemical compound C1C2=CC=NC=C2CN1CC1=CC=CC=C1 HTFXWAOSQODIBI-UHFFFAOYSA-N 0.000 description 1
- HEMROKPXTCOASZ-UHFFFAOYSA-N 2-bromo-1-[4-(trifluoromethyl)phenyl]ethanone Chemical compound FC(F)(F)C1=CC=C(C(=O)CBr)C=C1 HEMROKPXTCOASZ-UHFFFAOYSA-N 0.000 description 1
- JRQAAYVLPPGEHT-UHFFFAOYSA-N 2-bromoethylcyclohexane Chemical compound BrCCC1CCCCC1 JRQAAYVLPPGEHT-UHFFFAOYSA-N 0.000 description 1
- GLKAWMJFOFAAJA-UHFFFAOYSA-N 2-chloro-4-[4-[[4-(2,4-dichlorophenyl)-1-(4-nitrophenyl)imidazol-2-yl]methyl]phenyl]pyridine Chemical compound C1=CC([N+](=O)[O-])=CC=C1N1C(CC=2C=CC(=CC=2)C=2C=C(Cl)N=CC=2)=NC(C=2C(=CC(Cl)=CC=2)Cl)=C1 GLKAWMJFOFAAJA-UHFFFAOYSA-N 0.000 description 1
- SDTMFDGELKWGFT-UHFFFAOYSA-N 2-methylpropan-2-olate Chemical compound CC(C)(C)[O-] SDTMFDGELKWGFT-UHFFFAOYSA-N 0.000 description 1
- WFBUQJSXXDVYFZ-UHFFFAOYSA-N 2-methylpropane-2-sulfonyl chloride Chemical compound CC(C)(C)S(Cl)(=O)=O WFBUQJSXXDVYFZ-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- HECHWZPMWGJUEL-UHFFFAOYSA-N 2-tert-butyl-5-chloro-1,1-dioxo-1,2-thiazolidin-3-one Chemical compound CC(C)(C)N1C(=O)CC(Cl)S1(=O)=O HECHWZPMWGJUEL-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- SRVXSISGYBMIHR-UHFFFAOYSA-N 3-[3-[3-(2-amino-2-oxoethyl)phenyl]-5-chlorophenyl]-3-(5-methyl-1,3-thiazol-2-yl)propanoic acid Chemical compound S1C(C)=CN=C1C(CC(O)=O)C1=CC(Cl)=CC(C=2C=C(CC(N)=O)C=CC=2)=C1 SRVXSISGYBMIHR-UHFFFAOYSA-N 0.000 description 1
- OWGFTQNZELZNSV-UHFFFAOYSA-N 3-[4-[[4-(2,4-dichlorophenyl)-1-[4-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)phenyl]imidazol-2-yl]methyl]phenyl]benzoic acid Chemical compound OC(=O)C1=CC=CC(C=2C=CC(CC=3N(C=C(N=3)C=3C(=CC(Cl)=CC=3)Cl)C=3C=CC(=CC=3)N3S(NC(=O)C3)(=O)=O)=CC=2)=C1 OWGFTQNZELZNSV-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 description 1
- JVKJLZRWXBUBFN-UHFFFAOYSA-N 3-imidazol-1-ylaniline Chemical compound NC1=CC=CC(N2C=NC=C2)=C1 JVKJLZRWXBUBFN-UHFFFAOYSA-N 0.000 description 1
- DMBMXJJGPXADPO-UHFFFAOYSA-N 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(C=O)C=C1 DMBMXJJGPXADPO-UHFFFAOYSA-N 0.000 description 1
- YFCIFWOJYYFDQP-PTWZRHHISA-N 4-[3-amino-6-[(1S,3S,4S)-3-fluoro-4-hydroxycyclohexyl]pyrazin-2-yl]-N-[(1S)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl]-2-fluorobenzamide Chemical compound CNC[C@@H](NC(=O)c1ccc(cc1F)-c1nc(cnc1N)[C@H]1CC[C@H](O)[C@@H](F)C1)c1cc(F)cc(Br)c1 YFCIFWOJYYFDQP-PTWZRHHISA-N 0.000 description 1
- JHXXGNYUHFRWHO-UHFFFAOYSA-N 4-[4-[[4-(2,4-dichlorophenyl)-1-(4-nitrophenyl)imidazol-2-yl]methyl]phenyl]-1h-pyridin-2-one Chemical compound C1=CC([N+](=O)[O-])=CC=C1N1C(CC=2C=CC(=CC=2)C2=CC(=O)NC=C2)=NC(C=2C(=CC(Cl)=CC=2)Cl)=C1 JHXXGNYUHFRWHO-UHFFFAOYSA-N 0.000 description 1
- VKNQIDQANJKWNX-UHFFFAOYSA-N 4-[4-[[4-(2,4-dichlorophenyl)-1-(4-nitrophenyl)imidazol-2-yl]methyl]phenyl]phenol Chemical compound C1=CC(O)=CC=C1C(C=C1)=CC=C1CC1=NC(C=2C(=CC(Cl)=CC=2)Cl)=CN1C1=CC=C([N+]([O-])=O)C=C1 VKNQIDQANJKWNX-UHFFFAOYSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- JHFOWEGCZWLHNW-UHFFFAOYSA-N 4-fluoro-2-methyl-1-nitrobenzene Chemical compound CC1=CC(F)=CC=C1[N+]([O-])=O JHFOWEGCZWLHNW-UHFFFAOYSA-N 0.000 description 1
- 125000006306 4-iodophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1I 0.000 description 1
- OTLNPYWUJOZPPA-UHFFFAOYSA-N 4-nitrobenzoic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C=C1 OTLNPYWUJOZPPA-UHFFFAOYSA-N 0.000 description 1
- UTBULQCHEUWJNV-UHFFFAOYSA-N 4-phenylpiperidine Chemical compound C1CNCCC1C1=CC=CC=C1 UTBULQCHEUWJNV-UHFFFAOYSA-N 0.000 description 1
- XVCOLOAWZZGRFW-UHFFFAOYSA-N 5-(3-nitrophenyl)-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound [O-][N+](=O)C1=CC=CC(N2S(NC(=O)C2)(=O)=O)=C1 XVCOLOAWZZGRFW-UHFFFAOYSA-N 0.000 description 1
- IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 1
- CYVVWAYNYYROAP-UHFFFAOYSA-N 5-[2-chloro-4-[2-[[4-(4-cyclohexylphenyl)phenyl]methyl]-4-(2,4-dichlorophenyl)imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound ClC1=CC(Cl)=CC=C1C1=CN(C=2C=C(Cl)C(N3S(NC(=O)C3)(=O)=O)=CC=2)C(CC=2C=CC(=CC=2)C=2C=CC(=CC=2)C2CCCCC2)=N1 CYVVWAYNYYROAP-UHFFFAOYSA-N 0.000 description 1
- YGGUIDRKSYOYAB-UHFFFAOYSA-N 5-[3-[2-[(4-bromophenyl)methyl]-4-(2,4-difluorophenyl)imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound FC1=CC(F)=CC=C1C1=CN(C=2C=C(C=CC=2)N2S(NC(=O)C2)(=O)=O)C(CC=2C=CC(Br)=CC=2)=N1 YGGUIDRKSYOYAB-UHFFFAOYSA-N 0.000 description 1
- HQWVUJIVJIRRRL-UHFFFAOYSA-N 5-[3-[2-[[4-(3-cyclohexylprop-1-enyl)phenyl]methyl]-4-(2,4-dichlorophenyl)imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound ClC1=CC(Cl)=CC=C1C1=CN(C=2C=C(C=CC=2)N2S(NC(=O)C2)(=O)=O)C(CC=2C=CC(C=CCC3CCCCC3)=CC=2)=N1 HQWVUJIVJIRRRL-UHFFFAOYSA-N 0.000 description 1
- BIJVGGUSFZFYDP-UHFFFAOYSA-N 5-[3-[2-[[4-(4-bromophenyl)phenyl]methyl]-4-(2,4-dichlorophenyl)imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound ClC1=CC(Cl)=CC=C1C1=CN(C=2C=C(C=CC=2)N2S(NC(=O)C2)(=O)=O)C(CC=2C=CC(=CC=2)C=2C=CC(Br)=CC=2)=N1 BIJVGGUSFZFYDP-UHFFFAOYSA-N 0.000 description 1
- GYTKTXQLUKQIFC-UHFFFAOYSA-N 5-[3-[2-[[4-(4-butylphenyl)phenyl]methyl]-4-(2,4-dichlorophenyl)imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound C1=CC(CCCC)=CC=C1C(C=C1)=CC=C1CC1=NC(C=2C(=CC(Cl)=CC=2)Cl)=CN1C1=CC=CC(N2S(NC(=O)C2)(=O)=O)=C1 GYTKTXQLUKQIFC-UHFFFAOYSA-N 0.000 description 1
- UMORLHQAFJLCJI-UHFFFAOYSA-N 5-[3-[2-[[4-(6-cyclohexylpyridazin-3-yl)phenyl]methyl]-4-(2,4-dichlorophenyl)imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound ClC1=CC(Cl)=CC=C1C1=CN(C=2C=C(C=CC=2)N2S(NC(=O)C2)(=O)=O)C(CC=2C=CC(=CC=2)C=2N=NC(=CC=2)C2CCCCC2)=N1 UMORLHQAFJLCJI-UHFFFAOYSA-N 0.000 description 1
- DJPRRAJAOOBBOD-UHFFFAOYSA-N 5-[3-[2-[[4-[3-amino-4-(2-methylpropyl)phenyl]phenyl]methyl]-4-(2,4-dichlorophenyl)imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound C1=C(N)C(CC(C)C)=CC=C1C(C=C1)=CC=C1CC1=NC(C=2C(=CC(Cl)=CC=2)Cl)=CN1C1=CC=CC(N2S(NC(=O)C2)(=O)=O)=C1 DJPRRAJAOOBBOD-UHFFFAOYSA-N 0.000 description 1
- YSJUQKKCECWQKE-UHFFFAOYSA-N 5-[3-[2-[[4-[4-(2-cyclohexylethenyl)phenyl]phenyl]methyl]-4-(2,4-dichlorophenyl)imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound ClC1=CC(Cl)=CC=C1C1=CN(C=2C=C(C=CC=2)N2S(NC(=O)C2)(=O)=O)C(CC=2C=CC(=CC=2)C=2C=CC(C=CC3CCCCC3)=CC=2)=N1 YSJUQKKCECWQKE-UHFFFAOYSA-N 0.000 description 1
- VDAZFZQBPKYYGZ-UHFFFAOYSA-N 5-[3-[2-[[4-[4-(cyclohexylmethylamino)phenyl]phenyl]methyl]-4-(2,4-dichlorophenyl)imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound ClC1=CC(Cl)=CC=C1C1=CN(C=2C=C(C=CC=2)N2S(NC(=O)C2)(=O)=O)C(CC=2C=CC(=CC=2)C=2C=CC(NCC3CCCCC3)=CC=2)=N1 VDAZFZQBPKYYGZ-UHFFFAOYSA-N 0.000 description 1
- LNIFSZOACJPILF-UHFFFAOYSA-N 5-[3-[2-[[4-[4-(cyclohexylmethylsulfonyl)phenyl]phenyl]methyl]-4-(2,4-dichlorophenyl)imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound ClC1=CC(Cl)=CC=C1C1=CN(C=2C=C(C=CC=2)N2S(NC(=O)C2)(=O)=O)C(CC=2C=CC(=CC=2)C=2C=CC(=CC=2)S(=O)(=O)CC2CCCCC2)=N1 LNIFSZOACJPILF-UHFFFAOYSA-N 0.000 description 1
- XEIKYSCBQQFYNY-UHFFFAOYSA-N 5-[3-[2-[[4-[6-(cyclohexen-1-yl)pyridazin-3-yl]phenyl]methyl]-4-(2,4-dichlorophenyl)imidazol-1-yl]phenyl]-1,1-dioxo-2-(2-trimethylsilylethoxymethyl)-1,2,5-thiadiazolidin-3-one Chemical compound O=S1(=O)N(COCC[Si](C)(C)C)C(=O)CN1C1=CC=CC(N2C(=NC(=C2)C=2C(=CC(Cl)=CC=2)Cl)CC=2C=CC(=CC=2)C=2N=NC(=CC=2)C=2CCCCC=2)=C1 XEIKYSCBQQFYNY-UHFFFAOYSA-N 0.000 description 1
- LNHLSXKSWWIMNJ-UHFFFAOYSA-N 5-[3-[2-[[4-[6-(cyclohexylmethoxy)pyridazin-3-yl]phenyl]methyl]-4-(2,4-dichlorophenyl)imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound ClC1=CC(Cl)=CC=C1C1=CN(C=2C=C(C=CC=2)N2S(NC(=O)C2)(=O)=O)C(CC=2C=CC(=CC=2)C=2N=NC(OCC3CCCCC3)=CC=2)=N1 LNHLSXKSWWIMNJ-UHFFFAOYSA-N 0.000 description 1
- ZZYSLPXFDZNBRQ-UHFFFAOYSA-N 5-[3-[4-(2,4-dichlorophenyl)-2-[(4-iodophenyl)methyl]imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound ClC1=CC(Cl)=CC=C1C1=CN(C=2C=C(C=CC=2)N2S(NC(=O)C2)(=O)=O)C(CC=2C=CC(I)=CC=2)=N1 ZZYSLPXFDZNBRQ-UHFFFAOYSA-N 0.000 description 1
- PVBIFYXTXLAEAR-UHFFFAOYSA-N 5-[3-[4-(2,4-dichlorophenyl)-2-[(4-pent-1-enylphenyl)methyl]imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound C1=CC(C=CCCC)=CC=C1CC1=NC(C=2C(=CC(Cl)=CC=2)Cl)=CN1C1=CC=CC(N2S(NC(=O)C2)(=O)=O)=C1 PVBIFYXTXLAEAR-UHFFFAOYSA-N 0.000 description 1
- FJCRLKTVZWRYOD-UHFFFAOYSA-N 5-[3-[4-(2,4-dichlorophenyl)-2-[[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl]imidazol-1-yl]phenyl]-1,1-dioxo-2-(2-trimethylsilylethoxymethyl)-1,2,5-thiadiazolidin-3-one Chemical compound O1C(C)(C)C(C)(C)OB1C(C=C1)=CC=C1CC1=NC(C=2C(=CC(Cl)=CC=2)Cl)=CN1C1=CC=CC(N2S(N(COCC[Si](C)(C)C)C(=O)C2)(=O)=O)=C1 FJCRLKTVZWRYOD-UHFFFAOYSA-N 0.000 description 1
- WNUYANRPABBFMF-UHFFFAOYSA-N 5-[3-[4-(2,4-dichlorophenyl)-2-[[4-(4-methylpent-1-enyl)phenyl]methyl]imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound C1=CC(C=CCC(C)C)=CC=C1CC1=NC(C=2C(=CC(Cl)=CC=2)Cl)=CN1C1=CC=CC(N2S(NC(=O)C2)(=O)=O)=C1 WNUYANRPABBFMF-UHFFFAOYSA-N 0.000 description 1
- UCORWHRDQRWAHU-UHFFFAOYSA-N 5-[3-[4-(2,4-dichlorophenyl)-2-[[4-(4-phenoxyphenyl)phenyl]methyl]imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound ClC1=CC(Cl)=CC=C1C1=CN(C=2C=C(C=CC=2)N2S(NC(=O)C2)(=O)=O)C(CC=2C=CC(=CC=2)C=2C=CC(OC=3C=CC=CC=3)=CC=2)=N1 UCORWHRDQRWAHU-UHFFFAOYSA-N 0.000 description 1
- JWHQVPMHQVVZLR-UHFFFAOYSA-N 5-[3-[4-(2,4-dichlorophenyl)-2-[[4-(5-methylhex-1-enyl)phenyl]methyl]imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound C1=CC(C=CCCC(C)C)=CC=C1CC1=NC(C=2C(=CC(Cl)=CC=2)Cl)=CN1C1=CC=CC(N2S(NC(=O)C2)(=O)=O)=C1 JWHQVPMHQVVZLR-UHFFFAOYSA-N 0.000 description 1
- OZEALLJOKCIWHB-UHFFFAOYSA-N 5-[3-[4-(2,4-dichlorophenyl)-2-[[4-(6-sulfanylidene-1h-pyridazin-3-yl)phenyl]methyl]imidazol-1-yl]phenyl]-1,1-dioxo-2-(2-trimethylsilylethoxymethyl)-1,2,5-thiadiazolidin-3-one Chemical compound O=S1(=O)N(COCC[Si](C)(C)C)C(=O)CN1C1=CC=CC(N2C(=NC(=C2)C=2C(=CC(Cl)=CC=2)Cl)CC=2C=CC(=CC=2)C=2N=NC(S)=CC=2)=C1 OZEALLJOKCIWHB-UHFFFAOYSA-N 0.000 description 1
- JVKJRJRAQPIGEN-UHFFFAOYSA-N 5-[3-[4-(2,4-dichlorophenyl)-2-[[4-[4-(4,4-dimethylpent-1-enyl)phenyl]phenyl]methyl]imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound C1=CC(C=CCC(C)(C)C)=CC=C1C(C=C1)=CC=C1CC1=NC(C=2C(=CC(Cl)=CC=2)Cl)=CN1C1=CC=CC(N2S(NC(=O)C2)(=O)=O)=C1 JVKJRJRAQPIGEN-UHFFFAOYSA-N 0.000 description 1
- PNSVBNQXLNPDRQ-UHFFFAOYSA-N 5-[3-[4-(2,4-dichlorophenyl)-2-[[4-[4-(4,4-dimethylpentyl)phenyl]phenyl]methyl]imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound C1=CC(CCCC(C)(C)C)=CC=C1C(C=C1)=CC=C1CC1=NC(C=2C(=CC(Cl)=CC=2)Cl)=CN1C1=CC=CC(N2S(NC(=O)C2)(=O)=O)=C1 PNSVBNQXLNPDRQ-UHFFFAOYSA-N 0.000 description 1
- OTLKZGZRJKASEX-UHFFFAOYSA-N 5-[3-[[2-(2,4-dichlorophenyl)-2-oxoethyl]amino]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound ClC1=CC(Cl)=CC=C1C(=O)CNC1=CC=CC(N2S(NC(=O)C2)(=O)=O)=C1 OTLKZGZRJKASEX-UHFFFAOYSA-N 0.000 description 1
- TXUXRVCSIJREBK-UHFFFAOYSA-N 5-[4-[2-[(4-bromophenyl)methyl]-4-(2,6-dichlorophenyl)imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound ClC1=CC=CC(Cl)=C1C1=CN(C=2C=CC(=CC=2)N2S(NC(=O)C2)(=O)=O)C(CC=2C=CC(Br)=CC=2)=N1 TXUXRVCSIJREBK-UHFFFAOYSA-N 0.000 description 1
- AMCKIRQJZIOXCS-UHFFFAOYSA-N 5-[4-[2-[4-(4-tert-butylphenyl)phenyl]-5-(2,4-dichlorophenyl)-1h-imidazol-4-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound C1=CC(C(C)(C)C)=CC=C1C1=CC=C(C=2NC(=C(N=2)C=2C(=CC(Cl)=CC=2)Cl)C=2C=CC(=CC=2)N2S(NC(=O)C2)(=O)=O)C=C1 AMCKIRQJZIOXCS-UHFFFAOYSA-N 0.000 description 1
- VQLWLCGFWORYLD-UHFFFAOYSA-N 5-[4-[2-[4-(4-tert-butylphenyl)phenyl]-5-(2,4-dichlorophenyl)-3-(2-trimethylsilylethoxymethyl)imidazol-4-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound C1=CC(C(C)(C)C)=CC=C1C1=CC=C(C=2N(C(C=3C=CC(=CC=3)N3S(NC(=O)C3)(=O)=O)=C(N=2)C=2C(=CC(Cl)=CC=2)Cl)COCC[Si](C)(C)C)C=C1 VQLWLCGFWORYLD-UHFFFAOYSA-N 0.000 description 1
- XZOWVJVEKHBGNV-UHFFFAOYSA-N 5-[4-[2-[[4-(1-cyclohexyl-2-oxopyridin-4-yl)phenyl]methyl]-4-(2,4-dichlorophenyl)imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound ClC1=CC(Cl)=CC=C1C1=CN(C=2C=CC(=CC=2)N2S(NC(=O)C2)(=O)=O)C(CC=2C=CC(=CC=2)C2=CC(=O)N(C3CCCCC3)C=C2)=N1 XZOWVJVEKHBGNV-UHFFFAOYSA-N 0.000 description 1
- PSEHGYMMEMIQMI-UHFFFAOYSA-N 5-[4-[2-[[4-(4-butan-2-ylphenyl)phenyl]methyl]-4-(2,4-dichlorophenyl)imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound C1=CC(C(C)CC)=CC=C1C(C=C1)=CC=C1CC1=NC(C=2C(=CC(Cl)=CC=2)Cl)=CN1C1=CC=C(N2S(NC(=O)C2)(=O)=O)C=C1 PSEHGYMMEMIQMI-UHFFFAOYSA-N 0.000 description 1
- LJKBNNWBLNTKGJ-UHFFFAOYSA-N 5-[4-[2-[[4-(4-cyclohexylphenyl)phenyl]methyl]-4-(2,4-dichlorophenyl)imidazol-1-yl]-2-methylphenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound CC1=CC(N2C(=NC(=C2)C=2C(=CC(Cl)=CC=2)Cl)CC=2C=CC(=CC=2)C=2C=CC(=CC=2)C2CCCCC2)=CC=C1N1CC(=O)NS1(=O)=O LJKBNNWBLNTKGJ-UHFFFAOYSA-N 0.000 description 1
- JWBFNUUJHTWYFS-UHFFFAOYSA-N 5-[4-[2-[[4-(4-cyclohexylphenyl)phenyl]methyl]-4-(2,4-dichlorophenyl)imidazol-1-yl]-3-methylphenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound CC1=CC(N2S(NC(=O)C2)(=O)=O)=CC=C1N1C=C(C=2C(=CC(Cl)=CC=2)Cl)N=C1CC(C=C1)=CC=C1C(C=C1)=CC=C1C1CCCCC1 JWBFNUUJHTWYFS-UHFFFAOYSA-N 0.000 description 1
- BDZVMCRBYZTXOC-UHFFFAOYSA-N 5-[4-[2-[[4-(4-cyclohexylphenyl)phenyl]methyl]-4-(2,4-difluorophenyl)imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound FC1=CC(F)=CC=C1C1=CN(C=2C=CC(=CC=2)N2S(NC(=O)C2)(=O)=O)C(CC=2C=CC(=CC=2)C=2C=CC(=CC=2)C2CCCCC2)=N1 BDZVMCRBYZTXOC-UHFFFAOYSA-N 0.000 description 1
- VPQYXOYZSBHZRY-UHFFFAOYSA-N 5-[4-[2-[[4-(4-cyclopentylphenyl)phenyl]methyl]-4-(2,4-dichlorophenyl)imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound ClC1=CC(Cl)=CC=C1C1=CN(C=2C=CC(=CC=2)N2S(NC(=O)C2)(=O)=O)C(CC=2C=CC(=CC=2)C=2C=CC(=CC=2)C2CCCC2)=N1 VPQYXOYZSBHZRY-UHFFFAOYSA-N 0.000 description 1
- FIACFHPPELURQV-UHFFFAOYSA-N 5-[4-[2-[[4-(4-tert-butylphenyl)phenyl]methyl]-4-(2,4-difluorophenyl)imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound C1=CC(C(C)(C)C)=CC=C1C(C=C1)=CC=C1CC1=NC(C=2C(=CC(F)=CC=2)F)=CN1C1=CC=C(N2S(NC(=O)C2)(=O)=O)C=C1 FIACFHPPELURQV-UHFFFAOYSA-N 0.000 description 1
- QHRYOYFXHBYVQX-UHFFFAOYSA-N 5-[4-[2-[[4-(4-tert-butylphenyl)phenyl]methyl]-5-(2,4-dichlorophenyl)-1h-imidazol-4-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound C1=CC(C(C)(C)C)=CC=C1C(C=C1)=CC=C1CC1=NC(C=2C(=CC(Cl)=CC=2)Cl)=C(C=2C=CC(=CC=2)N2S(NC(=O)C2)(=O)=O)N1 QHRYOYFXHBYVQX-UHFFFAOYSA-N 0.000 description 1
- JGVDEEKCFUSQEL-UHFFFAOYSA-N 5-[4-[2-[[4-(5-cyclohexylpyridin-2-yl)phenyl]methyl]-4-(2,4-dichlorophenyl)imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound ClC1=CC(Cl)=CC=C1C1=CN(C=2C=CC(=CC=2)N2S(NC(=O)C2)(=O)=O)C(CC=2C=CC(=CC=2)C=2N=CC(=CC=2)C2CCCCC2)=N1 JGVDEEKCFUSQEL-UHFFFAOYSA-N 0.000 description 1
- FFTPLSPKYFZZDQ-UHFFFAOYSA-N 5-[4-[2-[[4-(5-cyclohexylpyridin-2-yl)phenyl]methyl]-4-(2,4-dichlorophenyl)imidazol-1-yl]phenyl]-1,1-dioxo-2-(2-trimethylsilylethoxymethyl)-1,2,5-thiadiazolidin-3-one Chemical compound O=S1(=O)N(COCC[Si](C)(C)C)C(=O)CN1C1=CC=C(N2C(=NC(=C2)C=2C(=CC(Cl)=CC=2)Cl)CC=2C=CC(=CC=2)C=2N=CC(=CC=2)C2CCCCC2)C=C1 FFTPLSPKYFZZDQ-UHFFFAOYSA-N 0.000 description 1
- ICFWMFVEKMCEJN-UHFFFAOYSA-N 5-[4-[2-[[4-[3-(butylamino)-4-(2-methylpropyl)phenyl]phenyl]methyl]-4-(2,4-dichlorophenyl)imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound C1=C(CC(C)C)C(NCCCC)=CC(C=2C=CC(CC=3N(C=C(N=3)C=3C(=CC(Cl)=CC=3)Cl)C=3C=CC(=CC=3)N3S(NC(=O)C3)(=O)=O)=CC=2)=C1 ICFWMFVEKMCEJN-UHFFFAOYSA-N 0.000 description 1
- LSYHLCJNFFRFLZ-UHFFFAOYSA-N 5-[4-[2-[[4-[4-(2-cyclohexylethoxy)phenyl]phenyl]methyl]-4-(2,4-dichlorophenyl)imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound ClC1=CC(Cl)=CC=C1C1=CN(C=2C=CC(=CC=2)N2S(NC(=O)C2)(=O)=O)C(CC=2C=CC(=CC=2)C=2C=CC(OCCC3CCCCC3)=CC=2)=N1 LSYHLCJNFFRFLZ-UHFFFAOYSA-N 0.000 description 1
- SOTFPBXFLYDGQI-UHFFFAOYSA-N 5-[4-[2-[[4-[4-(2-cyclopentylethyl)phenyl]phenyl]methyl]-4-(2,4-dichlorophenyl)imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound ClC1=CC(Cl)=CC=C1C1=CN(C=2C=CC(=CC=2)N2S(NC(=O)C2)(=O)=O)C(CC=2C=CC(=CC=2)C=2C=CC(CCC3CCCC3)=CC=2)=N1 SOTFPBXFLYDGQI-UHFFFAOYSA-N 0.000 description 1
- NEVUBJSMJKQTMT-UHFFFAOYSA-N 5-[4-[2-[[4-[5-(cyclohexen-1-yl)pyridin-2-yl]phenyl]methyl]-4-(2,4-dichlorophenyl)imidazol-1-yl]phenyl]-1,1-dioxo-2-(2-trimethylsilylethoxymethyl)-1,2,5-thiadiazolidin-3-one Chemical compound O=S1(=O)N(COCC[Si](C)(C)C)C(=O)CN1C1=CC=C(N2C(=NC(=C2)C=2C(=CC(Cl)=CC=2)Cl)CC=2C=CC(=CC=2)C=2N=CC(=CC=2)C=2CCCCC=2)C=C1 NEVUBJSMJKQTMT-UHFFFAOYSA-N 0.000 description 1
- NNPLPVCDVXMMJA-UHFFFAOYSA-N 5-[4-[2-[[4-[6-(2-cyclohexylethoxy)pyridazin-3-yl]phenyl]methyl]-4-(2,4-dichlorophenyl)imidazol-1-yl]phenyl]-1,1-dioxo-2-(2-trimethylsilylethoxymethyl)-1,2,5-thiadiazolidin-3-one Chemical compound O=S1(=O)N(COCC[Si](C)(C)C)C(=O)CN1C1=CC=C(N2C(=NC(=C2)C=2C(=CC(Cl)=CC=2)Cl)CC=2C=CC(=CC=2)C=2N=NC(OCCC3CCCCC3)=CC=2)C=C1 NNPLPVCDVXMMJA-UHFFFAOYSA-N 0.000 description 1
- ZYVRXKKNOOFMDX-UHFFFAOYSA-N 5-[4-[4-(2,4-dichlorophenyl)-2-[(4-hex-1-ynylphenyl)methyl]imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound C1=CC(C#CCCCC)=CC=C1CC1=NC(C=2C(=CC(Cl)=CC=2)Cl)=CN1C1=CC=C(N2S(NC(=O)C2)(=O)=O)C=C1 ZYVRXKKNOOFMDX-UHFFFAOYSA-N 0.000 description 1
- GLXKBDCEGJDTMH-UHFFFAOYSA-N 5-[4-[4-(2,4-dichlorophenyl)-2-[(4-iodophenyl)methyl]imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound ClC1=CC(Cl)=CC=C1C1=CN(C=2C=CC(=CC=2)N2S(NC(=O)C2)(=O)=O)C(CC=2C=CC(I)=CC=2)=N1 GLXKBDCEGJDTMH-UHFFFAOYSA-N 0.000 description 1
- ABAMHMIHPQIICI-UHFFFAOYSA-N 5-[4-[4-(2,4-dichlorophenyl)-2-[[4-(3-hydroxyphenyl)phenyl]methyl]imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound OC1=CC=CC(C=2C=CC(CC=3N(C=C(N=3)C=3C(=CC(Cl)=CC=3)Cl)C=3C=CC(=CC=3)N3S(NC(=O)C3)(=O)=O)=CC=2)=C1 ABAMHMIHPQIICI-UHFFFAOYSA-N 0.000 description 1
- FUGBATGBVYXSAR-UHFFFAOYSA-N 5-[4-[4-(2,4-dichlorophenyl)-2-[[4-(3-propan-2-ylphenyl)phenyl]methyl]imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound CC(C)C1=CC=CC(C=2C=CC(CC=3N(C=C(N=3)C=3C(=CC(Cl)=CC=3)Cl)C=3C=CC(=CC=3)N3S(NC(=O)C3)(=O)=O)=CC=2)=C1 FUGBATGBVYXSAR-UHFFFAOYSA-N 0.000 description 1
- FQBCXUACVMWIAG-UHFFFAOYSA-N 5-[4-[4-(2,4-dichlorophenyl)-2-[[4-(3-propoxyphenyl)phenyl]methyl]imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound CCCOC1=CC=CC(C=2C=CC(CC=3N(C=C(N=3)C=3C(=CC(Cl)=CC=3)Cl)C=3C=CC(=CC=3)N3S(NC(=O)C3)(=O)=O)=CC=2)=C1 FQBCXUACVMWIAG-UHFFFAOYSA-N 0.000 description 1
- YIMWBBKYUNXTFS-UHFFFAOYSA-N 5-[4-[4-(2,4-dichlorophenyl)-2-[[4-(4-heptan-4-ylphenyl)phenyl]methyl]imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound C1=CC(C(CCC)CCC)=CC=C1C(C=C1)=CC=C1CC1=NC(C=2C(=CC(Cl)=CC=2)Cl)=CN1C1=CC=C(N2S(NC(=O)C2)(=O)=O)C=C1 YIMWBBKYUNXTFS-UHFFFAOYSA-N 0.000 description 1
- DVOJXPJVVQTYBC-UHFFFAOYSA-N 5-[4-[4-(2,4-dichlorophenyl)-2-[[4-(4-pentan-3-ylphenyl)phenyl]methyl]imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound C1=CC(C(CC)CC)=CC=C1C(C=C1)=CC=C1CC1=NC(C=2C(=CC(Cl)=CC=2)Cl)=CN1C1=CC=C(N2S(NC(=O)C2)(=O)=O)C=C1 DVOJXPJVVQTYBC-UHFFFAOYSA-N 0.000 description 1
- RSDCJDSHMWGFAS-UHFFFAOYSA-N 5-[4-[4-(2,4-dichlorophenyl)-2-[[4-(4-phenylpiperidin-1-yl)phenyl]methyl]imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound ClC1=CC(Cl)=CC=C1C1=CN(C=2C=CC(=CC=2)N2S(NC(=O)C2)(=O)=O)C(CC=2C=CC(=CC=2)N2CCC(CC2)C=2C=CC=CC=2)=N1 RSDCJDSHMWGFAS-UHFFFAOYSA-N 0.000 description 1
- JKADRRIFRFXVDX-UHFFFAOYSA-N 5-[4-[4-(2,4-dichlorophenyl)-2-[[4-(4-piperazin-1-ylphenyl)phenyl]methyl]imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound ClC1=CC(Cl)=CC=C1C1=CN(C=2C=CC(=CC=2)N2S(NC(=O)C2)(=O)=O)C(CC=2C=CC(=CC=2)C=2C=CC(=CC=2)N2CCNCC2)=N1 JKADRRIFRFXVDX-UHFFFAOYSA-N 0.000 description 1
- BQBNPZZGNZAHIM-UHFFFAOYSA-N 5-[4-[4-(2,4-dichlorophenyl)-2-[[4-(4-propanoylphenyl)phenyl]methyl]imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound C1=CC(C(=O)CC)=CC=C1C(C=C1)=CC=C1CC1=NC(C=2C(=CC(Cl)=CC=2)Cl)=CN1C1=CC=C(N2S(NC(=O)C2)(=O)=O)C=C1 BQBNPZZGNZAHIM-UHFFFAOYSA-N 0.000 description 1
- ZRADIEILTHTASJ-UHFFFAOYSA-N 5-[4-[4-(2,4-dichlorophenyl)-2-[[4-(4-propoxyphenyl)phenyl]methyl]imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound C1=CC(OCCC)=CC=C1C(C=C1)=CC=C1CC1=NC(C=2C(=CC(Cl)=CC=2)Cl)=CN1C1=CC=C(N2S(NC(=O)C2)(=O)=O)C=C1 ZRADIEILTHTASJ-UHFFFAOYSA-N 0.000 description 1
- WTNSHEANXLUETQ-UHFFFAOYSA-N 5-[4-[4-(2,4-dichlorophenyl)-2-[[4-[3-(3,3-dimethylbutoxy)phenyl]phenyl]methyl]imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound CC(C)(C)CCOC1=CC=CC(C=2C=CC(CC=3N(C=C(N=3)C=3C(=CC(Cl)=CC=3)Cl)C=3C=CC(=CC=3)N3S(NC(=O)C3)(=O)=O)=CC=2)=C1 WTNSHEANXLUETQ-UHFFFAOYSA-N 0.000 description 1
- XKQHIUOSXNDCPK-UHFFFAOYSA-N 5-[4-[4-(2,4-dichlorophenyl)-2-[[4-[3-(diethylamino)-4-(2-methylpropyl)phenyl]phenyl]methyl]imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound C1=C(CC(C)C)C(N(CC)CC)=CC(C=2C=CC(CC=3N(C=C(N=3)C=3C(=CC(Cl)=CC=3)Cl)C=3C=CC(=CC=3)N3S(NC(=O)C3)(=O)=O)=CC=2)=C1 XKQHIUOSXNDCPK-UHFFFAOYSA-N 0.000 description 1
- QMMAMSWJZZLFGF-UHFFFAOYSA-N 5-[4-[4-(2,4-dichlorophenyl)-2-[[4-[4-(3,3-dimethylbutoxy)phenyl]phenyl]methyl]imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound C1=CC(OCCC(C)(C)C)=CC=C1C(C=C1)=CC=C1CC1=NC(C=2C(=CC(Cl)=CC=2)Cl)=CN1C1=CC=C(N2S(NC(=O)C2)(=O)=O)C=C1 QMMAMSWJZZLFGF-UHFFFAOYSA-N 0.000 description 1
- CDHABIPUSIRJGK-UHFFFAOYSA-N 5-[4-[4-(2,4-dichlorophenyl)-2-[[4-[4-(3-oxo-4-propan-2-ylpiperazin-1-yl)phenyl]phenyl]methyl]imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound C1C(=O)N(C(C)C)CCN1C1=CC=C(C=2C=CC(CC=3N(C=C(N=3)C=3C(=CC(Cl)=CC=3)Cl)C=3C=CC(=CC=3)N3S(NC(=O)C3)(=O)=O)=CC=2)C=C1 CDHABIPUSIRJGK-UHFFFAOYSA-N 0.000 description 1
- BWGFWXBOXWPINH-UHFFFAOYSA-N 5-[4-[4-(2,4-dichlorophenyl)-2-[[4-[4-(3-oxopiperazin-1-yl)phenyl]phenyl]methyl]imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound ClC1=CC(Cl)=CC=C1C1=CN(C=2C=CC(=CC=2)N2S(NC(=O)C2)(=O)=O)C(CC=2C=CC(=CC=2)C=2C=CC(=CC=2)N2CC(=O)NCC2)=N1 BWGFWXBOXWPINH-UHFFFAOYSA-N 0.000 description 1
- CCPMTPUZKIXVSM-UHFFFAOYSA-N 5-[4-[4-(2,4-dichlorophenyl)-2-[[4-[4-(4-ethyl-3-oxopiperazin-1-yl)phenyl]phenyl]methyl]imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound C1C(=O)N(CC)CCN1C1=CC=C(C=2C=CC(CC=3N(C=C(N=3)C=3C(=CC(Cl)=CC=3)Cl)C=3C=CC(=CC=3)N3S(NC(=O)C3)(=O)=O)=CC=2)C=C1 CCPMTPUZKIXVSM-UHFFFAOYSA-N 0.000 description 1
- XQHMTMCTFPXCEM-UHFFFAOYSA-N 5-[4-[4-(2,4-dichlorophenyl)-2-[[4-[4-(4-methylpiperazin-1-yl)phenyl]phenyl]methyl]imidazol-1-yl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound C1CN(C)CCN1C1=CC=C(C=2C=CC(CC=3N(C=C(N=3)C=3C(=CC(Cl)=CC=3)Cl)C=3C=CC(=CC=3)N3S(NC(=O)C3)(=O)=O)=CC=2)C=C1 XQHMTMCTFPXCEM-UHFFFAOYSA-N 0.000 description 1
- LLODOISSGDKRPL-UHFFFAOYSA-N 5-[4-[[2-[(4-bromophenyl)methyl]-4-(2,4-dichlorophenyl)imidazol-1-yl]methyl]phenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound ClC1=CC(Cl)=CC=C1C(N=C1CC=2C=CC(Br)=CC=2)=CN1CC1=CC=C(N2S(NC(=O)C2)(=O)=O)C=C1 LLODOISSGDKRPL-UHFFFAOYSA-N 0.000 description 1
- FMPIWCOEKHEWPT-UHFFFAOYSA-N 5-[5-[2-[(4-bromophenyl)methyl]-4-(2,4-difluorophenyl)imidazol-1-yl]-2-methylphenyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Chemical compound CC1=CC=C(N2C(=NC(=C2)C=2C(=CC(F)=CC=2)F)CC=2C=CC(Br)=CC=2)C=C1N1CC(=O)NS1(=O)=O FMPIWCOEKHEWPT-UHFFFAOYSA-N 0.000 description 1
- OKRUMSWHDWKGHA-UHFFFAOYSA-N 5-bromopentanoyl chloride Chemical compound ClC(=O)CCCCBr OKRUMSWHDWKGHA-UHFFFAOYSA-N 0.000 description 1
- BLQVLJDDGUYUPN-UHFFFAOYSA-N 5-methylhex-1-enylboronic acid Chemical compound CC(C)CCC=CB(O)O BLQVLJDDGUYUPN-UHFFFAOYSA-N 0.000 description 1
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- OUMYCZNNPRRSLG-UHFFFAOYSA-N 7-oxabicyclo[4.1.0]hepta-1,3,5-trien-5-amine Chemical compound NC1=CC=CC2=C1O2 OUMYCZNNPRRSLG-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 229910015845 BBr3 Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 239000002053 C09CA06 - Candesartan Substances 0.000 description 1
- 229940124802 CB1 antagonist Drugs 0.000 description 1
- IAKXJVJUVAIMJE-UHFFFAOYSA-N CC(C)(C)O.N=C=O Chemical compound CC(C)(C)O.N=C=O IAKXJVJUVAIMJE-UHFFFAOYSA-N 0.000 description 1
- JAMASFBHYDBCDA-UHFFFAOYSA-M C[Br+].CC([O-])=O Chemical compound C[Br+].CC([O-])=O JAMASFBHYDBCDA-UHFFFAOYSA-M 0.000 description 1
- NGZYXUVDOHTDIC-UHFFFAOYSA-N C[Mg]C1CCCC1 Chemical compound C[Mg]C1CCCC1 NGZYXUVDOHTDIC-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- QWCKQJZIFLGMSD-GSVOUGTGSA-N D-alpha-aminobutyric acid Chemical compound CC[C@@H](N)C(O)=O QWCKQJZIFLGMSD-GSVOUGTGSA-N 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- 101100457919 Drosophila melanogaster stg gene Proteins 0.000 description 1
- 102000010778 Dual Specificity Phosphatase 1 Human genes 0.000 description 1
- 108010038537 Dual Specificity Phosphatase 1 Proteins 0.000 description 1
- 102100028987 Dual specificity protein phosphatase 2 Human genes 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
- 102000000393 Ghrelin Receptors Human genes 0.000 description 1
- 108010016122 Ghrelin Receptors Proteins 0.000 description 1
- 102000030595 Glucokinase Human genes 0.000 description 1
- 108010021582 Glucokinase Proteins 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 238000003747 Grignard reaction Methods 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 101000838335 Homo sapiens Dual specificity protein phosphatase 2 Proteins 0.000 description 1
- 101000624643 Homo sapiens M-phase inducer phosphatase 3 Proteins 0.000 description 1
- 101001080401 Homo sapiens Proteasome assembly chaperone 1 Proteins 0.000 description 1
- 101000580039 Homo sapiens Ras-specific guanine nucleotide-releasing factor 1 Proteins 0.000 description 1
- 101000606506 Homo sapiens Receptor-type tyrosine-protein phosphatase eta Proteins 0.000 description 1
- 101001087422 Homo sapiens Tyrosine-protein phosphatase non-receptor type 13 Proteins 0.000 description 1
- 101001087426 Homo sapiens Tyrosine-protein phosphatase non-receptor type 14 Proteins 0.000 description 1
- 101001087388 Homo sapiens Tyrosine-protein phosphatase non-receptor type 21 Proteins 0.000 description 1
- 101001135565 Homo sapiens Tyrosine-protein phosphatase non-receptor type 3 Proteins 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-O Imidazolium Chemical class C1=C[NH+]=CN1 RAXXELZNTBOGNW-UHFFFAOYSA-O 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- 101710176178 Kidney androgen-regulated protein Proteins 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- QWCKQJZIFLGMSD-VKHMYHEASA-N L-alpha-aminobutyric acid Chemical compound CC[C@H](N)C(O)=O QWCKQJZIFLGMSD-VKHMYHEASA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229940127470 Lipase Inhibitors Drugs 0.000 description 1
- 229940086609 Lipase inhibitor Drugs 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- 102100023330 M-phase inducer phosphatase 3 Human genes 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 101100085221 Mus musculus Ptprk gene Proteins 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 101710088428 Napsin-A Proteins 0.000 description 1
- 102400000064 Neuropeptide Y Human genes 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- 108010015832 Non-Receptor Type 2 Protein Tyrosine Phosphatase Proteins 0.000 description 1
- IDRGFNPZDVBSSE-UHFFFAOYSA-N OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F Chemical compound OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F IDRGFNPZDVBSSE-UHFFFAOYSA-N 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 229960005552 PAC-1 Drugs 0.000 description 1
- 102000023984 PPAR alpha Human genes 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Natural products C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100034086 Receptor-type tyrosine-protein phosphatase O Human genes 0.000 description 1
- 101710138738 Receptor-type tyrosine-protein phosphatase O Proteins 0.000 description 1
- 102100039808 Receptor-type tyrosine-protein phosphatase eta Human genes 0.000 description 1
- 101710189648 Serine/threonine-protein phosphatase Proteins 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 238000003477 Sonogashira cross-coupling reaction Methods 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 102100033014 Tyrosine-protein phosphatase non-receptor type 13 Human genes 0.000 description 1
- 102100033015 Tyrosine-protein phosphatase non-receptor type 14 Human genes 0.000 description 1
- 102100033141 Tyrosine-protein phosphatase non-receptor type 2 Human genes 0.000 description 1
- 102100033005 Tyrosine-protein phosphatase non-receptor type 21 Human genes 0.000 description 1
- 102100033131 Tyrosine-protein phosphatase non-receptor type 3 Human genes 0.000 description 1
- 238000006887 Ullmann reaction Methods 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- AKZWRTCWNXHHFR-PDIZUQLASA-N [(3S)-oxolan-3-yl] N-[(2S,3S)-4-[(5S)-5-benzyl-3-[(2R)-2-carbamoyloxy-2,3-dihydro-1H-inden-1-yl]-4-oxo-3H-pyrrol-5-yl]-3-hydroxy-1-phenylbutan-2-yl]carbamate Chemical compound NC(=O)O[C@@H]1Cc2ccccc2C1C1C=N[C@](C[C@H](O)[C@H](Cc2ccccc2)NC(=O)O[C@H]2CCOC2)(Cc2ccccc2)C1=O AKZWRTCWNXHHFR-PDIZUQLASA-N 0.000 description 1
- GMGWFDHLFMBIDS-XBXARRHUSA-N [(e)-3-phenylprop-1-enyl]boronic acid Chemical compound OB(O)\C=C\CC1=CC=CC=C1 GMGWFDHLFMBIDS-XBXARRHUSA-N 0.000 description 1
- OLTGERMANPOCTC-HWKANZROSA-N [(e)-4-methylpent-1-enyl]boronic acid Chemical compound CC(C)C\C=C\B(O)O OLTGERMANPOCTC-HWKANZROSA-N 0.000 description 1
- LDTJUGVTOZBIBN-VOTSOKGWSA-N [(e)-hept-1-enyl]boronic acid Chemical compound CCCCC\C=C\B(O)O LDTJUGVTOZBIBN-VOTSOKGWSA-N 0.000 description 1
- RBTAJLKAPFBZDQ-BQYQJAHWSA-N [(e)-oct-1-enyl]boronic acid Chemical compound CCCCCC\C=C\B(O)O RBTAJLKAPFBZDQ-BQYQJAHWSA-N 0.000 description 1
- SYKWJOZHNDPWIM-SNAWJCMRSA-N [(e)-pent-1-enyl]boronic acid Chemical compound CCC\C=C\B(O)O SYKWJOZHNDPWIM-SNAWJCMRSA-N 0.000 description 1
- MJRQDCWNCUPLRC-UHFFFAOYSA-N [3-(3,3-dimethylbutylsulfanyl)phenyl]boronic acid Chemical compound CC(C)(C)CCSC1=CC=CC(B(O)O)=C1 MJRQDCWNCUPLRC-UHFFFAOYSA-N 0.000 description 1
- CWLNHPXWZRALFS-UHFFFAOYSA-N [3-[(2-methylpropan-2-yl)oxycarbonylamino]phenyl]boronic acid Chemical compound CC(C)(C)OC(=O)NC1=CC=CC(B(O)O)=C1 CWLNHPXWZRALFS-UHFFFAOYSA-N 0.000 description 1
- YZSPHVWALUJQNK-UHFFFAOYSA-N [4-(2-methylpropyl)phenyl]boronic acid Chemical compound CC(C)CC1=CC=C(B(O)O)C=C1 YZSPHVWALUJQNK-UHFFFAOYSA-N 0.000 description 1
- ZSSSIAWGBKNYDP-UHFFFAOYSA-N [4-(3,3-dimethylbutoxy)phenyl]boronic acid Chemical compound CC(C)(C)CCOC1=CC=C(B(O)O)C=C1 ZSSSIAWGBKNYDP-UHFFFAOYSA-N 0.000 description 1
- OVNZUEJWYIMMSW-UHFFFAOYSA-N [4-(3-ethoxy-3-oxoprop-1-enyl)phenyl]boronic acid Chemical compound CCOC(=O)C=CC1=CC=C(B(O)O)C=C1 OVNZUEJWYIMMSW-UHFFFAOYSA-N 0.000 description 1
- PRCOGZNDLWXGHB-UHFFFAOYSA-N [4-(3-ethoxy-3-oxopropyl)phenyl]boronic acid Chemical compound CCOC(=O)CCC1=CC=C(B(O)O)C=C1 PRCOGZNDLWXGHB-UHFFFAOYSA-N 0.000 description 1
- SXRHIFFWZAAVOM-UHFFFAOYSA-N [4-(3-ethylcyclobutyl)phenyl]boronic acid Chemical compound C1C(CC)CC1C1=CC=C(B(O)O)C=C1 SXRHIFFWZAAVOM-UHFFFAOYSA-N 0.000 description 1
- YMTFCWRVSYNGBQ-UHFFFAOYSA-N [4-(4-methylpentyl)phenyl]boronic acid Chemical compound CC(C)CCCC1=CC=C(B(O)O)C=C1 YMTFCWRVSYNGBQ-UHFFFAOYSA-N 0.000 description 1
- LEEWRICIBNMZRW-UHFFFAOYSA-M [Br-].[Mg+]CC1CCCC1 Chemical compound [Br-].[Mg+]CC1CCCC1 LEEWRICIBNMZRW-UHFFFAOYSA-M 0.000 description 1
- KURZCZMGELAPSV-UHFFFAOYSA-N [Br].[I] Chemical compound [Br].[I] KURZCZMGELAPSV-UHFFFAOYSA-N 0.000 description 1
- XAQHXGSHRMHVMU-UHFFFAOYSA-N [S].[S] Chemical class [S].[S] XAQHXGSHRMHVMU-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 125000003302 alkenyloxy group Chemical group 0.000 description 1
- 150000001346 alkyl aryl ethers Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 125000005133 alkynyloxy group Chemical group 0.000 description 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- 229940127282 angiotensin receptor antagonist Drugs 0.000 description 1
- 150000003931 anilides Chemical group 0.000 description 1
- OMJUESTZKGXQKH-UHFFFAOYSA-N aniline;tert-butyl n-sulfamoylcarbamate Chemical class NC1=CC=CC=C1.CC(C)(C)OC(=O)NS(N)(=O)=O OMJUESTZKGXQKH-UHFFFAOYSA-N 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 125000005333 aroyloxy group Chemical group 0.000 description 1
- 125000005251 aryl acyl group Chemical group 0.000 description 1
- 150000001543 aryl boronic acids Chemical class 0.000 description 1
- 150000001501 aryl fluorides Chemical class 0.000 description 1
- 150000001502 aryl halides Chemical class 0.000 description 1
- 238000006254 arylation reaction Methods 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 108010014210 axokine Proteins 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- NDTSRXAMMQDVSW-UHFFFAOYSA-N benzthiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1N=C2CSCC1=CC=CC=C1 NDTSRXAMMQDVSW-UHFFFAOYSA-N 0.000 description 1
- 229960001541 benzthiazide Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 229920000080 bile acid sequestrant Polymers 0.000 description 1
- 229940096699 bile acid sequestrants Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 125000005620 boronic acid group Chemical class 0.000 description 1
- KDPAWGWELVVRCH-UHFFFAOYSA-N bromoacetic acid Chemical class OC(=O)CBr KDPAWGWELVVRCH-UHFFFAOYSA-N 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- UUWSLBWDFJMSFP-UHFFFAOYSA-N bromomethylcyclohexane Chemical compound BrCC1CCCCC1 UUWSLBWDFJMSFP-UHFFFAOYSA-N 0.000 description 1
- 125000004799 bromophenyl group Chemical group 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 description 1
- 229960000932 candesartan Drugs 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- RBHJBMIOOPYDBQ-UHFFFAOYSA-N carbon dioxide;propan-2-one Chemical compound O=C=O.CC(C)=O RBHJBMIOOPYDBQ-UHFFFAOYSA-N 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 101150069072 cdc25 gene Proteins 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- MVCQKIKWYUURMU-UHFFFAOYSA-N cetilistat Chemical compound C1=C(C)C=C2C(=O)OC(OCCCCCCCCCCCCCCCC)=NC2=C1 MVCQKIKWYUURMU-UHFFFAOYSA-N 0.000 description 1
- 229950002397 cetilistat Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229940090805 clavulanate Drugs 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 239000007819 coupling partner Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- XZWQKJXJNKYMAP-UHFFFAOYSA-N cyclohexen-1-ylboronic acid Chemical compound OB(O)C1=CCCCC1 XZWQKJXJNKYMAP-UHFFFAOYSA-N 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 230000020335 dealkylation Effects 0.000 description 1
- 238000006900 dealkylation reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical group [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 125000004119 disulfanediyl group Chemical group *SS* 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 229950005627 embonate Drugs 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000010931 ester hydrolysis Methods 0.000 description 1
- 229950000206 estolate Drugs 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000005677 ethinylene group Chemical class [*:2]C#C[*:1] 0.000 description 1
- MDNHHMOSLZNORK-UHFFFAOYSA-N ethyl 4-[4-[[5-(2,4-dichlorophenyl)-1h-imidazol-2-yl]methyl]phenyl]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1C(C=C1)=CC=C1CC1=NC(C=2C(=CC(Cl)=CC=2)Cl)=CN1 MDNHHMOSLZNORK-UHFFFAOYSA-N 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- 125000001543 furan-2,5-diyl group Chemical group O1C(=CC=C1*)* 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960003627 gemfibrozil Drugs 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 229940111120 gold preparations Drugs 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 239000001046 green dye Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- 239000003667 hormone antagonist Substances 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229940095990 inderal Drugs 0.000 description 1
- 230000000053 inderal effect Effects 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- OTCKOJUMXQWKQG-UHFFFAOYSA-L magnesium bromide Chemical compound [Mg+2].[Br-].[Br-] OTCKOJUMXQWKQG-UHFFFAOYSA-L 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- WJGVYRMMIIWBAU-UHFFFAOYSA-M magnesium;2-methylbutane;bromide Chemical compound [Mg+2].[Br-].CC(C)C[CH2-] WJGVYRMMIIWBAU-UHFFFAOYSA-M 0.000 description 1
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 1
- RYEXTBOQKFUPOE-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].CC[CH2-] RYEXTBOQKFUPOE-UHFFFAOYSA-M 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229960000299 mazindol Drugs 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- HLJRRXAXYNLZHK-UHFFFAOYSA-N methyl 2-[3-[2-[(4-bromophenyl)methyl]-4-(2,4-dichlorophenyl)imidazol-1-yl]anilino]acetate Chemical compound COC(=O)CNC1=CC=CC(N2C(=NC(=C2)C=2C(=CC(Cl)=CC=2)Cl)CC=2C=CC(Br)=CC=2)=C1 HLJRRXAXYNLZHK-UHFFFAOYSA-N 0.000 description 1
- ADEXGXYRYNTXEG-UHFFFAOYSA-N methyl 2-[3-[2-[[4-(4-butylphenyl)phenyl]methyl]-4-(2,4-dichlorophenyl)imidazol-1-yl]anilino]acetate Chemical compound C1=CC(CCCC)=CC=C1C(C=C1)=CC=C1CC1=NC(C=2C(=CC(Cl)=CC=2)Cl)=CN1C1=CC=CC(NCC(=O)OC)=C1 ADEXGXYRYNTXEG-UHFFFAOYSA-N 0.000 description 1
- ZYDFYKRLIBAKRD-UHFFFAOYSA-N methyl 2-[4-[2-[(4-bromophenyl)methyl]-4-(4-methylsulfonylphenyl)imidazol-1-yl]anilino]acetate Chemical compound C1=CC(NCC(=O)OC)=CC=C1N1C(CC=2C=CC(Br)=CC=2)=NC(C=2C=CC(=CC=2)S(C)(=O)=O)=C1 ZYDFYKRLIBAKRD-UHFFFAOYSA-N 0.000 description 1
- MMXCNGUFTHHIBA-UHFFFAOYSA-N methyl 2-[4-[2-[[4-(4-butan-2-ylphenyl)phenyl]methyl]-4-(2,4-dichlorophenyl)imidazol-1-yl]anilino]acetate Chemical compound C1=CC(C(C)CC)=CC=C1C(C=C1)=CC=C1CC1=NC(C=2C(=CC(Cl)=CC=2)Cl)=CN1C1=CC=C(NCC(=O)OC)C=C1 MMXCNGUFTHHIBA-UHFFFAOYSA-N 0.000 description 1
- TXWKHORQOBMSQC-UHFFFAOYSA-N methyl 2-[4-[2-[[4-(4-cyclohexylphenyl)phenyl]methyl]-4-(2,4-dichlorophenyl)imidazol-1-yl]anilino]acetate Chemical compound C1=CC(NCC(=O)OC)=CC=C1N1C(CC=2C=CC(=CC=2)C=2C=CC(=CC=2)C2CCCCC2)=NC(C=2C(=CC(Cl)=CC=2)Cl)=C1 TXWKHORQOBMSQC-UHFFFAOYSA-N 0.000 description 1
- NURTVXGLMVLMBR-UHFFFAOYSA-N methyl 2-[4-[2-[[4-(4-cyclohexylphenyl)phenyl]methyl]-4-(4-methylsulfonylphenyl)imidazol-1-yl]anilino]acetate Chemical compound C1=CC(NCC(=O)OC)=CC=C1N1C(CC=2C=CC(=CC=2)C=2C=CC(=CC=2)C2CCCCC2)=NC(C=2C=CC(=CC=2)S(C)(=O)=O)=C1 NURTVXGLMVLMBR-UHFFFAOYSA-N 0.000 description 1
- GUUJLMOEQMCRSB-UHFFFAOYSA-N methyl 2-[4-[4-(2,4-dichlorophenyl)-2-[[4-(4-pentylphenyl)phenyl]methyl]imidazol-1-yl]anilino]acetate Chemical compound C1=CC(CCCCC)=CC=C1C(C=C1)=CC=C1CC1=NC(C=2C(=CC(Cl)=CC=2)Cl)=CN1C1=CC=C(NCC(=O)OC)C=C1 GUUJLMOEQMCRSB-UHFFFAOYSA-N 0.000 description 1
- MSKTWXSXBGETPL-UHFFFAOYSA-N methyl 2-[4-[4-(2,4-dichlorophenyl)-2-[[4-(4-propanoylphenyl)phenyl]methyl]imidazol-1-yl]anilino]acetate Chemical compound C1=CC(C(=O)CC)=CC=C1C(C=C1)=CC=C1CC1=NC(C=2C(=CC(Cl)=CC=2)Cl)=CN1C1=CC=C(NCC(=O)OC)C=C1 MSKTWXSXBGETPL-UHFFFAOYSA-N 0.000 description 1
- OXWXMKLLYUIQIC-UHFFFAOYSA-N methyl 2-[4-[4-(2,4-dichlorophenyl)-2-[[4-(4-propylphenyl)phenyl]methyl]imidazol-1-yl]anilino]acetate Chemical compound C1=CC(CCC)=CC=C1C(C=C1)=CC=C1CC1=NC(C=2C(=CC(Cl)=CC=2)Cl)=CN1C1=CC=C(NCC(=O)OC)C=C1 OXWXMKLLYUIQIC-UHFFFAOYSA-N 0.000 description 1
- JTJGSRUPLMWHQV-UHFFFAOYSA-N methyl 4-[2-[(4-bromophenyl)methyl]-1-(4-nitrophenyl)imidazol-4-yl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1C1=CN(C=2C=CC(=CC=2)[N+]([O-])=O)C(CC=2C=CC(Br)=CC=2)=N1 JTJGSRUPLMWHQV-UHFFFAOYSA-N 0.000 description 1
- PPCQCSRKGHGAID-UHFFFAOYSA-N methyl 4-[2-[(4-bromophenyl)methyl]-1h-imidazol-5-yl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1C1=CNC(CC=2C=CC(Br)=CC=2)=N1 PPCQCSRKGHGAID-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- YNADRQHQKCKSCL-UHFFFAOYSA-N morpholine-2,4-diyl Chemical group C1C[O+]=CC[N-]1 YNADRQHQKCKSCL-UHFFFAOYSA-N 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- YCWSUKQGVSGXJO-NTUHNPAUSA-N nifuroxazide Chemical group C1=CC(O)=CC=C1C(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 YCWSUKQGVSGXJO-NTUHNPAUSA-N 0.000 description 1
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Substances [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 230000009543 pathological alteration Effects 0.000 description 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229950010879 phenamine Drugs 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000003934 phosphoprotein phosphatase inhibitor Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000008375 physiological alteration Effects 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000002810 primary assay Methods 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- IVRIRQXJSNCSPQ-UHFFFAOYSA-N propan-2-yl carbonochloridate Chemical compound CC(C)OC(Cl)=O IVRIRQXJSNCSPQ-UHFFFAOYSA-N 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 238000002805 secondary assay Methods 0.000 description 1
- XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-N sodium;2-hydroxybenzoic acid Chemical compound [Na+].OC(=O)C1=CC=CC=C1O ABBQHOQBGMUPJH-UHFFFAOYSA-N 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- QAHVHSLSRLSVGS-UHFFFAOYSA-N sulfamoyl chloride Chemical compound NS(Cl)(=O)=O QAHVHSLSRLSVGS-UHFFFAOYSA-N 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical compound [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 150000003463 sulfur Chemical class 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- XTQHKBHJIVJGKJ-UHFFFAOYSA-N sulfur monoxide Chemical class S=O XTQHKBHJIVJGKJ-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000012622 synthetic inhibitor Substances 0.000 description 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- PWQLFIKTGRINFF-UHFFFAOYSA-N tert-butyl 4-hydroxypiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(O)CC1 PWQLFIKTGRINFF-UHFFFAOYSA-N 0.000 description 1
- VYTZACAVIFXMSS-UHFFFAOYSA-N tert-butyl n-[3-(2-tert-butyl-1,1,3-trioxo-1,2-thiazol-5-yl)phenyl]carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=CC(C=2S(N(C(C)(C)C)C(=O)C=2)(=O)=O)=C1 VYTZACAVIFXMSS-UHFFFAOYSA-N 0.000 description 1
- FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003509 tertiary alcohols Chemical class 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- RLTPJVKHGBFGQA-UHFFFAOYSA-N thiadiazolidine Chemical compound C1CSNN1 RLTPJVKHGBFGQA-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 229960002784 thioridazine Drugs 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 1
- 229960002277 tolazamide Drugs 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 1
- 229960003991 trazodone Drugs 0.000 description 1
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 229940066528 trichloroacetate Drugs 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-O triethylammonium ion Chemical compound CC[NH+](CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-O 0.000 description 1
- UORVGPXVDQYIDP-UHFFFAOYSA-N trihydridoboron Substances B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- NHDIQVFFNDKAQU-UHFFFAOYSA-N tripropan-2-yl borate Chemical compound CC(C)OB(OC(C)C)OC(C)C NHDIQVFFNDKAQU-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- HGBOYTHUEUWSSQ-UHFFFAOYSA-N valeric aldehyde Natural products CCCCC=O HGBOYTHUEUWSSQ-UHFFFAOYSA-N 0.000 description 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US76325606P | 2006-01-30 | 2006-01-30 | |
| US60/763,256 | 2006-01-30 | ||
| PCT/US2007/002675 WO2007089857A2 (en) | 2006-01-30 | 2007-01-30 | Substituted imidazole derivatives and their use as ptpase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0707338A2 true BRPI0707338A2 (pt) | 2011-05-03 |
Family
ID=38042619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0707338-0A BRPI0707338A2 (pt) | 2006-01-30 | 2007-01-30 | derivados de imidazol, composições, e métodos substituìdos de uso como inibidores de ptpase |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US7723369B2 (enExample) |
| EP (1) | EP1991544B1 (enExample) |
| JP (1) | JP5180099B2 (enExample) |
| KR (1) | KR20080094806A (enExample) |
| CN (1) | CN101374835B (enExample) |
| AU (1) | AU2007211319B9 (enExample) |
| BR (1) | BRPI0707338A2 (enExample) |
| CA (1) | CA2637024C (enExample) |
| EA (1) | EA019385B1 (enExample) |
| IL (1) | IL192557A (enExample) |
| NZ (1) | NZ569329A (enExample) |
| WO (1) | WO2007089857A2 (enExample) |
| ZA (1) | ZA200805648B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2551909C (en) * | 2004-02-12 | 2011-10-11 | Transtech Pharma, Inc. | Substituted azole derivatives, compositions, and methods of use |
| US7723369B2 (en) * | 2006-01-30 | 2010-05-25 | Transtech Pharma, Inc. | Substituted imidazole derivatives, compositions, and methods of use as PTPase inhibitors |
| SG176628A1 (en) | 2009-06-05 | 2012-01-30 | Link Medicine Corp | Aminopyrrolidinone derivatives and uses thereof |
| WO2011007819A1 (ja) | 2009-07-17 | 2011-01-20 | 塩野義製薬株式会社 | ラクタムまたはベンゼンスルホンアミド化合物を含有する医薬 |
| JP5398076B2 (ja) * | 2009-12-10 | 2014-01-29 | 四国化成工業株式会社 | 2−(ブロモベンジル)−4−(ブロモフェニル)−5−メチルイミダゾール化合物 |
| JP5398075B2 (ja) * | 2010-01-13 | 2014-01-29 | 四国化成工業株式会社 | 4−(ジクロロフェニル)−2−(4−フルオロベンジル)−5−メチルイミダゾール化合物 |
| BR112013004882A2 (pt) | 2010-08-31 | 2016-05-03 | Snu R&Db Foundation | utilização de reprogramação fetal de agonista ppar delta |
| JP5809157B2 (ja) | 2010-10-08 | 2015-11-10 | 持田製薬株式会社 | 環状アミド誘導体 |
| WO2012094580A2 (en) | 2011-01-07 | 2012-07-12 | High Point Pharmaceuticals, Llc | Compounds that modulate oxidative stress |
| CA2834465A1 (en) | 2011-04-28 | 2012-11-01 | Mochida Pharmaceutical Co., Ltd. | Cyclic amide derivative |
| US10696642B2 (en) | 2015-09-23 | 2020-06-30 | The General Hospital Corporation | TEAD transcription factor autopalmitoylation inhibitors |
| EP3770146B1 (en) | 2015-10-07 | 2024-07-24 | Astellas Engineered Small Molecules US, Incorporated | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| CN109071459B (zh) * | 2016-04-13 | 2022-08-16 | 米托布里奇公司 | Ppar激动剂、化合物、药物组合物以及它们的使用方法 |
| ES2908801T3 (es) | 2016-06-07 | 2022-05-04 | Jacobio Pharmaceuticals Co Ltd | Nuevos derivados heterocíclicos útiles como inhibidores de SHP2 |
| DK3601239T3 (da) | 2017-03-23 | 2024-09-30 | Jacobio Pharmaceuticals Co Ltd | Novel heterocyclic derivatives useful as shp2 inhibitors |
| AU2019290197B2 (en) * | 2018-06-21 | 2023-08-24 | Abbvie Inc. | Protein tyrosine phosphatase inhibitors and methods of use thereof |
| CN112839935A (zh) | 2018-09-26 | 2021-05-25 | 北京加科思新药研发有限公司 | 可用作shp2抑制剂的新型杂环衍生物 |
| MX2021011209A (es) | 2019-03-15 | 2022-01-19 | Massachusetts Gen Hospital | Novedosos inhibidores de molécula pequeña de factores de transcripción tead. |
| US11058695B2 (en) * | 2019-11-08 | 2021-07-13 | Myongji University Industry And Academia Cooperation Foundation | Inhibitor of carbapenem-hydrolyzing class D beta-lactamases |
| EP4192817A1 (en) * | 2020-08-10 | 2023-06-14 | Dana-Farber Cancer Institute, Inc. | Substituted 1,2,4-oxadiazoles as small molecule inhibitors of ubiquitin-specific protease 28 |
| EP4225435B1 (en) * | 2020-10-09 | 2024-12-11 | Bristol-Myers Squibb Company | Aminoimidazole fpr2 agonists |
| EP4227299A4 (en) * | 2020-10-12 | 2025-04-09 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | GLP-1 RECEPTOR AGONIST, BENZIMIDAZOLONE AND ITS USE |
| CN117658947A (zh) * | 2022-09-06 | 2024-03-08 | 杭州中美华东制药有限公司 | 蛋白酪氨酸磷酸酶抑制作用的5-(取代芳基)-1,2,5-噻二唑啉-3-酮类化合物 |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63276054A (ja) | 1987-05-07 | 1988-11-14 | Hitachi Chem Co Ltd | 電子写真感光体 |
| CA2009925C (en) | 1989-02-14 | 2002-10-01 | Koichi Kondo | Method for enhancement of chemiluminescence |
| DE69311145T2 (de) | 1992-01-23 | 1998-02-05 | Inst Francais Du Petrol | Katalysator für die Alkylierung von Olefinen |
| DE69330713T2 (de) | 1992-03-13 | 2002-07-04 | Merck Sharp & Dohme Ltd., Hoddesdon | Imidazol-, triazol- und tetrazolderivate |
| US5348969A (en) | 1992-04-03 | 1994-09-20 | Bristol-Myers Squibb Company | Diphenyloxazolyl-oxazoles as platelet aggregation inhibitors |
| WO1994008982A1 (fr) | 1992-10-13 | 1994-04-28 | Nippon Soda Co., Ltd. | Derives oxazole et thiazole |
| CA2171610A1 (en) | 1993-09-14 | 1995-03-23 | Gideon A. Rodan | Cdna encoding a novel human protein tyrosine phosphatase |
| US5616601A (en) | 1994-07-28 | 1997-04-01 | Gd Searle & Co | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation |
| US5700816A (en) | 1995-06-12 | 1997-12-23 | Isakson; Peter C. | Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor |
| JPH11507670A (ja) | 1995-06-12 | 1999-07-06 | ジー.ディー.サール アンド カンパニー | シクロオキシゲナーゼ−2インヒビターと5−リポキシゲナーゼインヒビターの組合せによる炎症と炎症関連疾患の治療 |
| US5753687A (en) | 1995-06-19 | 1998-05-19 | Ontogen Corporation | Modulators of proteins with phosphotryrosine recognition units |
| US6388076B1 (en) | 1995-06-19 | 2002-05-14 | Ontogen Corporation | Protein tyrosine phosphatase-inhibiting compounds |
| JP3849157B2 (ja) | 1995-08-01 | 2006-11-22 | 東ソー株式会社 | 2−イミダゾリン類の製造法 |
| US6238902B1 (en) | 1996-03-22 | 2001-05-29 | Genentech, Inc. | Protein tyrosine phosphatases |
| US5958957A (en) | 1996-04-19 | 1999-09-28 | Novo Nordisk A/S | Modulators of molecules with phosphotyrosine recognition units |
| CA2275610A1 (en) * | 1996-12-16 | 1998-06-25 | Ontogen Corporation | Modulators of proteins with phosphotyrosine recognition units |
| US5840721A (en) | 1997-07-09 | 1998-11-24 | Ontogen Corporation | Imidazole derivatives as MDR modulators |
| GB9715816D0 (en) | 1997-07-25 | 1997-10-01 | Black James Foundation | Histamine H receptor ligands |
| FR2767527B1 (fr) | 1997-08-25 | 1999-11-12 | Pf Medicament | Derives de piperazines indoliques, utiles comme medicaments et procede de preparation |
| WO1999011606A2 (en) | 1997-08-28 | 1999-03-11 | Pharmacia & Upjohn Company | Inhibitors of protein tyrosine phosphatase |
| US6169087B1 (en) | 1997-09-23 | 2001-01-02 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (PTPases) |
| US5972986A (en) | 1997-10-14 | 1999-10-26 | G.D. Searle & Co. | Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia |
| US6159944A (en) * | 1998-02-27 | 2000-12-12 | Synchroneuron, Llc | Method for treating painful conditions of the anal region and compositions therefor |
| US20020002199A1 (en) | 1998-03-12 | 2002-01-03 | Lone Jeppesen | Modulators of protein tyrosine phosphatases (ptpases) |
| US6262044B1 (en) | 1998-03-12 | 2001-07-17 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (PTPASES) |
| US6699896B1 (en) | 1998-05-12 | 2004-03-02 | Wyeth | Oxazole-aryl-carboxylic acids useful in the treatment of insulin resistance and hyperglycemia |
| WO1999061410A1 (en) | 1998-05-12 | 1999-12-02 | American Home Products Corporation | 2,3,5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia |
| US20030194745A1 (en) | 1998-06-26 | 2003-10-16 | Mcdowell Robert S. | Cysteine mutants and methods for detecting ligand binding to biological molecules |
| JP2004514402A (ja) | 1998-07-24 | 2004-05-20 | メルク フロスト カナダ アンド カンパニー | プロテインチロシンホスファターゼ−1b(ptp−1b)欠失マウスおよびその使用 |
| US6174874B1 (en) | 1998-09-21 | 2001-01-16 | Merck Frosst Canada & Co. | Phosphonic acids derivatives as inhibitors of protein tyrosine phosphate 1B (PTP-1B) |
| US6534056B1 (en) | 1998-12-11 | 2003-03-18 | Mcgill University | Therapeutic and diagnostic uses of protein tyrosine phosphatase TC-PTP |
| JP4221129B2 (ja) | 1999-02-15 | 2009-02-12 | 富士フイルム株式会社 | 含窒素ヘテロ環化合物、有機発光素子材料、有機発光素子 |
| AU4738600A (en) | 1999-05-14 | 2000-12-05 | Merck Frosst Canada & Co. | Phosphonic and carboxylic acid derivatives as inhibitors of protein tyrosine phosphatase-1b (ptp-1b) |
| DE60007697T2 (de) | 1999-07-21 | 2004-12-09 | F. Hoffmann-La Roche Ag | Triazolderivate |
| JP2003508382A (ja) | 1999-08-27 | 2003-03-04 | スージェン・インコーポレーテッド | リン酸模倣体およびホスファターゼ阻害剤を用いる治療方法 |
| US6410556B1 (en) | 1999-09-10 | 2002-06-25 | Novo Nordisk A/S | Modulators of protein tyrosine phosphateses (PTPases) |
| CN1414951A (zh) | 1999-10-28 | 2003-04-30 | 基本治疗公司 | 药剂排出泵抑制药 |
| US6624182B1 (en) | 1999-11-25 | 2003-09-23 | Ciba Specialty Chemicals Corporation | Hydroxyphenylvinylthiazoles |
| US6777433B2 (en) | 1999-12-22 | 2004-08-17 | Merck Frosst Canada & Co. | Protein tyrosine phosphatase 1B (PTP-1B) inhibitors containing two ortho-substituted aromatic phosphonates |
| WO2001046206A1 (en) | 1999-12-22 | 2001-06-28 | Merck Frosst Canada & Co. | Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1b (ptp-1b) |
| JP2003518128A (ja) | 1999-12-22 | 2003-06-03 | メルク フロスト カナダ アンド カンパニー | タンパク質チロシンホスファターゼ1b(ptp−1b)のインヒビターとなる芳香族ホスホネート |
| US6486141B2 (en) | 1999-12-22 | 2002-11-26 | Merck Frosst Canada & Co. | Phosphonic acid biaryl derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B) |
| WO2001046205A1 (en) | 1999-12-22 | 2001-06-28 | Merck Frosst Canada & Co. | Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1b (ptp-1b) |
| JP2003520049A (ja) | 2000-01-18 | 2003-07-02 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | ヒトタンパク質であるチロシンホスファターゼのポリヌクレオチド、ポリペプチド、および抗体 |
| TWI284639B (en) | 2000-01-24 | 2007-08-01 | Shionogi & Co | A compound having thrombopoietin receptor agonistic effect |
| EP1257824A2 (en) | 2000-02-14 | 2002-11-20 | Ceptyr, Inc. | Improved assay for protein tyrosine phosphatases |
| AU4398801A (en) | 2000-03-22 | 2001-10-03 | Banyu Pharmaceutical Co., Ltd. | Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors |
| US6627647B1 (en) | 2000-03-23 | 2003-09-30 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted 1-(4-aminophenyl)imidazoles and their use as anti-inflammatory agents |
| AU2001258784A1 (en) | 2000-05-22 | 2001-12-03 | Takeda Chemical Industries Ltd. | Tyrosine phosphatase inhibitors |
| IL153804A0 (en) | 2000-07-06 | 2003-07-31 | Array Biopharma Inc | Tyrosine derivatives as phosphatase inhibitors |
| US6613903B2 (en) | 2000-07-07 | 2003-09-02 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (PTPases) |
| US20020099073A1 (en) | 2000-07-07 | 2002-07-25 | Andersen Henrik Sune | Modulators of protein tyrosine phosphatases (PTPases) |
| US6627767B2 (en) | 2000-08-29 | 2003-09-30 | Abbott Laboratories | Amino(oxo) acetic acid protein tyrosine phosphatase inhibitors |
| US20020035137A1 (en) | 2000-08-29 | 2002-03-21 | Gang Liu | Amino (oxo) acetic acid protein tyrosine phosphatase inhibitors |
| US20020169157A1 (en) | 2000-08-29 | 2002-11-14 | Gang Liu | Selective protein tyrosine phosphatatase inhibitors |
| US6472545B2 (en) | 2000-08-29 | 2002-10-29 | Abbott Laboratories | Protein tyrosine phosphatase inhibitors |
| US6972340B2 (en) | 2000-08-29 | 2005-12-06 | Abbott Laboratories | Selective protein tyrosine phosphatatase inhibitors |
| GB0022079D0 (en) | 2000-09-08 | 2000-10-25 | Inst Of Molecul & Cell Biology | Novel protein tyrosine phosphatase inhibitor |
| JP2002114768A (ja) | 2000-10-11 | 2002-04-16 | Japan Tobacco Inc | 2−(2,5−ジハロゲン−3,4−ジヒドロキシフェニル)アゾール化合物及びそれを含有してなる医薬組成物 |
| US20030108883A1 (en) | 2001-02-13 | 2003-06-12 | Rondinone Cristina M. | Methods for identifying compounds that inhibit or reduce PTP1B expression |
| US20030120073A1 (en) | 2001-04-25 | 2003-06-26 | Seto Christopher T. | Alpha-ketocarboxylic acid based inhibitors of phosphoryl tyrosine phosphatases |
| JP2002322054A (ja) | 2001-04-26 | 2002-11-08 | Dai Ichi Seiyaku Co Ltd | 薬剤排出ポンプ阻害薬 |
| US7163932B2 (en) | 2001-06-20 | 2007-01-16 | Merck Frosst Canada & Co. | Aryldifluoromethylphosphonic acids for treatment of diabetes |
| US20030064979A1 (en) | 2001-06-29 | 2003-04-03 | Hansen Thomas Kruse | Method of inhibiting PTP 1B and /or T-cell PTP and/or other PTPases with an Asp residue at position 48 |
| US20030170660A1 (en) | 2001-07-11 | 2003-09-11 | Sondergaard Helle Bach | P387L variant in protein tyrosine phosphatase-1B is associated with type 2 diabetes and impaired serine phosphorylation of PTP-1B in vitro |
| EP1435951B1 (en) | 2001-10-12 | 2006-01-18 | Bayer Pharmaceuticals Corporation | Phenyl substituted 5-membered nitrogen containing heterocycles for the tretment of obesity |
| JP2005508355A (ja) | 2001-10-19 | 2005-03-31 | トランス テック ファーマ,インコーポレイテッド | 治療薬としてのビス−ヘテロアリールアルカン |
| ES2278064T3 (es) | 2001-10-19 | 2007-08-01 | Transtech Pharma Inc. | Derivados de beta-carbolina como inhibidores de ptp. |
| CA2469228A1 (en) | 2001-12-03 | 2003-06-12 | Japan Tobacco Inc. | Azole compound and medicinal use thereof |
| JP2003231679A (ja) | 2001-12-03 | 2003-08-19 | Japan Tobacco Inc | アゾール化合物及びその医薬用途 |
| US6642381B2 (en) | 2001-12-27 | 2003-11-04 | Hoffman-La Roche Inc. | Pyrimido[5,4-e][1,2,4]triazine-5,7-diamine compounds as protein tyrosine phosphatase inhibitors |
| US20030180827A1 (en) | 2002-01-04 | 2003-09-25 | Aventis Pharma Deutschland Gmbh. | Highly sensitive and continuous protein tyrosine phosphatase test using 6,8-difluoro-4-methylumbelliferyl phosphate |
| US20030215899A1 (en) | 2002-02-13 | 2003-11-20 | Ceptyr, Inc. | Reversible oxidation of protein tyrosine phosphatases |
| US6784205B2 (en) | 2002-03-01 | 2004-08-31 | Sunesis Pharmaceuticals, Inc. | Compounds that modulate the activity of PTP-1B and TC-PTP |
| DK1482931T3 (da) | 2002-03-05 | 2011-12-19 | Transtech Pharma Inc | Mono- og bicycliske azolderivater der inhiberer interaktionen af ligander med RAGE |
| US7291635B2 (en) | 2002-04-03 | 2007-11-06 | Novartis Ag | 5-substituted 1,1-dioxo-1,2,5,-thiadiazolidin-3-one derivatives |
| BR0309305A (pt) | 2002-04-12 | 2005-02-15 | Pfizer | Compostos de imidazol como agentes antiinflamatórios e analgésicos |
| JP2003313172A (ja) | 2002-04-23 | 2003-11-06 | Tosoh Corp | N−置換イミダゾール化合物の製造方法 |
| JP4529342B2 (ja) | 2002-04-23 | 2010-08-25 | 東ソー株式会社 | 環状アミジニウム有機酸塩の製造方法 |
| US20040009956A1 (en) | 2002-04-29 | 2004-01-15 | Dehua Pei | Inhibition of protein tyrosine phosphatases and SH2 domains by a neutral phosphotyrosine mimetic |
| AU2003239897A1 (en) | 2002-05-23 | 2003-12-12 | Ceptyr, Inc. | Modulation of ptp1b signal transduction by rna interference |
| US6849761B2 (en) | 2002-09-05 | 2005-02-01 | Wyeth | Substituted naphthoic acid derivatives useful in the treatment of insulin resistance and hyperglycemia |
| EP1402888A1 (en) | 2002-09-18 | 2004-03-31 | Jerini AG | The use of substituted carbocyclic compounds as rotamases inhibitors |
| WO2004062664A1 (en) | 2002-12-30 | 2004-07-29 | Vertex Pharmaceuticals Incorporated | Sulfhydantoins as phosphate isosteres for use as phosphatase inhibitors in the treatment of cancer and autoimmune disorders |
| US7279576B2 (en) | 2002-12-31 | 2007-10-09 | Deciphera Pharmaceuticals, Llc | Anti-cancer medicaments |
| US7144911B2 (en) | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
| JP2006518738A (ja) | 2003-02-12 | 2006-08-17 | トランス テック ファーマ,インコーポレイテッド | 治療薬としての置換アゾール誘導体 |
| WO2004071448A2 (en) | 2003-02-12 | 2004-08-26 | Transtech Pharma Inc. | Substituted azole derivatives as inhibitors of protein tyrosine phosphatases |
| US20040167188A1 (en) | 2003-02-14 | 2004-08-26 | Zhili Xin | Protein-tyrosine phosphatase inhibitors and uses thereof |
| KR20050119201A (ko) | 2003-04-09 | 2005-12-20 | 니뽄 다바코 산교 가부시키가이샤 | 5원 헤테로방향족 고리 화합물 및 이의 의약적 용도 |
| WO2005035551A2 (en) * | 2003-10-08 | 2005-04-21 | Incyte Corporation | Inhibitors of proteins that bind phosphorylated molecules |
| CA2551909C (en) * | 2004-02-12 | 2011-10-11 | Transtech Pharma, Inc. | Substituted azole derivatives, compositions, and methods of use |
| CA2630448A1 (en) * | 2005-12-08 | 2007-06-14 | Novartis Ag | 1,1,3-trioxo-1,2,5-thiadiazolidines and their use as ptp-ases inhibitors |
| WO2007067613A1 (en) * | 2005-12-08 | 2007-06-14 | Novartis Ag | 1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (ptpase) |
| US7723369B2 (en) * | 2006-01-30 | 2010-05-25 | Transtech Pharma, Inc. | Substituted imidazole derivatives, compositions, and methods of use as PTPase inhibitors |
-
2007
- 2007-01-30 US US11/699,780 patent/US7723369B2/en not_active Expired - Fee Related
- 2007-01-30 CN CN2007800039423A patent/CN101374835B/zh not_active Expired - Fee Related
- 2007-01-30 NZ NZ569329A patent/NZ569329A/en not_active IP Right Cessation
- 2007-01-30 AU AU2007211319A patent/AU2007211319B9/en not_active Ceased
- 2007-01-30 JP JP2008553332A patent/JP5180099B2/ja not_active Expired - Fee Related
- 2007-01-30 WO PCT/US2007/002675 patent/WO2007089857A2/en not_active Ceased
- 2007-01-30 BR BRPI0707338-0A patent/BRPI0707338A2/pt not_active IP Right Cessation
- 2007-01-30 KR KR1020087021180A patent/KR20080094806A/ko not_active Ceased
- 2007-01-30 ZA ZA200805648A patent/ZA200805648B/xx unknown
- 2007-01-30 EP EP07763040.8A patent/EP1991544B1/en active Active
- 2007-01-30 CA CA2637024A patent/CA2637024C/en not_active Expired - Fee Related
- 2007-01-30 EA EA200870218A patent/EA019385B1/ru not_active IP Right Cessation
-
2008
- 2008-07-01 IL IL192557A patent/IL192557A/en not_active IP Right Cessation
-
2010
- 2010-01-11 US US12/685,178 patent/US8404731B2/en not_active Expired - Fee Related
-
2012
- 2012-03-06 US US13/412,747 patent/US20120196906A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20070191385A1 (en) | 2007-08-16 |
| ZA200805648B (en) | 2009-09-30 |
| IL192557A0 (en) | 2009-02-11 |
| KR20080094806A (ko) | 2008-10-24 |
| HK1127342A1 (en) | 2009-09-25 |
| IL192557A (en) | 2013-09-30 |
| US20100113331A1 (en) | 2010-05-06 |
| WO2007089857A2 (en) | 2007-08-09 |
| CA2637024A1 (en) | 2007-08-09 |
| US20120196906A1 (en) | 2012-08-02 |
| JP2009525340A (ja) | 2009-07-09 |
| US8404731B2 (en) | 2013-03-26 |
| EA019385B1 (ru) | 2014-03-31 |
| CN101374835A (zh) | 2009-02-25 |
| WO2007089857A3 (en) | 2008-06-26 |
| EA200870218A1 (ru) | 2009-02-27 |
| NZ569329A (en) | 2011-09-30 |
| AU2007211319A1 (en) | 2007-08-09 |
| US7723369B2 (en) | 2010-05-25 |
| AU2007211319B2 (en) | 2012-01-19 |
| EP1991544B1 (en) | 2018-08-15 |
| CA2637024C (en) | 2013-05-14 |
| AU2007211319B9 (en) | 2012-05-31 |
| JP5180099B2 (ja) | 2013-04-10 |
| CN101374835B (zh) | 2012-04-25 |
| EP1991544A2 (en) | 2008-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0707338A2 (pt) | derivados de imidazol, composições, e métodos substituìdos de uso como inibidores de ptpase | |
| US7998995B2 (en) | LXR and FXR modulators | |
| EP1124804B1 (en) | Prostaglandin endoperoxide h synthase biosynthesis inhibitors | |
| TWI498115B (zh) | 咪唑羰基化合物 | |
| AU2006261841A1 (en) | Pyrazole based LXR modulators | |
| JP2006518738A (ja) | 治療薬としての置換アゾール誘導体 | |
| BRPI0915876B1 (pt) | Composto azol, composição farmacêutica e uso do dito composto para tratamento da dor neuropática | |
| CZ292942B6 (cs) | Derivát (N-hydroxykarbamoyl)-1-(4-fenoxy)benzensulfonylu | |
| EA021359B1 (ru) | N-((6-аминопиридин-3-ил)метил)гетероарилкарбоксамиды в качестве ингибиторов калликреина в плазме | |
| US20060058329A1 (en) | Pyrazole inhibitors of the transforming growth factor | |
| AU2023212015B2 (en) | Pyrrolidine compounds | |
| MXPA04009961A (es) | Compuestos de imidazol como agentes anti-inflamatorios y analgesicos. | |
| CZ20013155A3 (cs) | Inhibitory metaloproteas | |
| WO2006109846A1 (ja) | トリアゾール誘導体およびその用途 | |
| BRPI0817824B1 (pt) | derivados de (r)-4-(heteroaril) feniletila, composições farmacêuticas e processo para preparação dos mesmos | |
| JP2012508225A (ja) | ピロリジン | |
| KR100938817B1 (ko) | 안지오텐신 ⅱ 작용제로 유용한 삼중고리 화합물 | |
| SG178043A1 (en) | Substituted benzamide derivatives as glucokinase (gk) activators | |
| JP2020529449A (ja) | 高カリウム血症を処置するためのグリチルレチン酸誘導体 | |
| EP1373262A2 (en) | Azacycloalkyl substituted acetic acid derivatives for use as mmp inhibitors | |
| HK1127342B (en) | Substituted imidazole derivatives and there use as ptpase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 3A ANUIDADE. |
|
| B08H | Application fees: decision cancelled [chapter 8.8 patent gazette] |
Free format text: REFERENTE A DESPACHO 8.6 NA RPI 2161 DE 05/06/2012. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |